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Acute myeloid leukemia (AML) is a rare disease in adults with an increasing incidence and 
relatively low five-year survival rate. Unfortunately, the underlying mechanism of 
leukemogenesis is poorly known, while there has been little progress in the treatment for 
AML. Studies have shown that X-linked inhibitor of apoptosis protein (XIAP) is highly 
expressed and contributes to chemoresistance in AML, and there is a correlation between 
high XIAP levels and poor overall survival in AML patients. Hence, a novel drug, RO-BIR2, 
which was developed by a pharmaceutical company, that targets the Baculovirus Inhibitor of 
Apoptosis Protein Repeat 2 (BIR2) domain in XIAP to reactivate blocked apoptosis is a 
potentially promising therapy to treat AML. In this project, we determined the efficacy of 
RO-BIR2 in both AML cell lines and patient samples and investigated possible synergism 
with TRAIL and chemotherapeutic drug Cytarbine (Ara-C). Combination therapy resulted in 
high synergistic effect in AML cells, along with increase in caspase 3/7 activity, increase in 
specific apoptotic population and changes in the levels of apoptotic-related protein, such as 
cleaved caspase 3, caspase 7, and Bax. Besides, we investigated the underlying mechanism of 
RO-BIR2’s different responses on U-937 cells compared to other AML cells, and found 




LIST OF TABLES 
 
Table 1.1 FAB subtypes of AML, MO-M7 [7] ....................................................................... 20 
Table 1.2 Drug discovery of XIAP BIR3 and BIR2 Inhibitors ............................................... 28 
Table 4.1 AML cell lines and FAB subtypes ........................................................................... 52 
Table 4.2   CI value of RO-BIR2 and Ara-C combination therapy on U-937 cells ................. 81 
Table 4.3   CI value of RO-BIR2 and Ara-C combination therapy on AML patient samples 82 
Table 4.4 Functional clusters for unique down-regulated genes in U-937 ............................ 100 
Table 4.5 Top networks of unique regulated genes on U-937 cells ....................................... 102 
















LIST OF FIGURES 
 
Figure 1.1 Five-year survival rate of AML (2005-2011, SEER 2015). ................................... 19 
Figure 1.2 New cases and deaths of AML in US (SEER 2015). ............................................. 19 
Figure 1.3 FAB subtypes of AML, M0-M7. ............................................................................ 20 
Figure 1.4. Pre-apoptotic cells, early apoptotic cells and late apoptotic cells. ........................ 23 
Figure 1.5. Six hallmarks of cancer. ........................................................................................ 23 
Figure 1.6 Extrinsic pathway and intrinsic pathway of apotosis. ............................................ 25 
Figure 1.7. The structure of XIAP. .......................................................................................... 26 
Figure 4.1 XIAP expression level among AML subtypes ....................................................... 44 
Figure 4.2 Correlation of XIAP level and AML patients overall survival .............................. 44 
Figure 4.3 Overall survival-XIAP gene expression associations among AML FAB subtypes
.................................................................................................................................................. 46 
Figure 4.4. Monotherapy and Combination therapy on SW-620 cells .................................... 49 
Figure 4.5 CI calculation of RO-BIR2 and TRAIL combination on SW620 cells .................. 50 
Figure 4.6 XIAP expression level on AML cell lines and AML patient samples ................... 52 
Figure 4.7 Cell proliferation assay analysis of RO-BIR2 monotherapy on AML cell lines .... 54 
Figure 4.8 Dose-effect curve of RO-BIR2 monotherapy on U-937 cells (48hr) ..................... 54 
Figure 4.9 Cell proliferation assay analysis of RO-BIR2 monotherapy on AML patient 
samples ..................................................................................................................................... 56 
Figure 4.10 Dose-effect curve of RO-BIR2 monotherapy on AML patient samples (48hr) ... 57 
Figure 4.11. Apoptosis assay of FACS on RO-BIR2 treated KG-1 cells ................................ 59 
Figure 4.12 apoptotic cell populations of KG-1 and U-937 cells upon RO-BIR2 treatment 
(48hr)........................................................................................................................................ 60 
Figure 4.13 Caspase 3/7 activity on AML cell lines and patient samples upon RO-BIR2 
monotherapy ............................................................................................................................ 60 
Figure 4.14 Western blot analyses of AML cells after RO-BIR2 monotherapy ..................... 62 
Figure 4.15  Model of TRAIL and RO-BIR2 combination therapy ........................................ 63 
Figure 4.16 Cell viability assay and CI value of BIR2-TRAIL combination treatment on U-
937 cells ................................................................................................................................... 65 
Figure 4.17 Cell viability assay and CI value of BIR2-TRAIL combination treatment on HL-
60 cells ..................................................................................................................................... 66 
11 
 
Figure 4.18 Cell proliferation assay and CI value of BIR2-TRAIL combination treatment on 
patient sample AD330 cells ..................................................................................................... 68 
Figure 4.19 Apoptosis assay on OCI-AML3 cells upon RO-BIR2 and TRAIL combination 
treatment (72hr) ....................................................................................................................... 70 
Figure 4.20 Apoptotic cell population of AML cell lines upon combination therapy of RO-
BIR2 and TRAIL (72hr) .......................................................................................................... 71 
Figure 4.21 Apoptosis assay on patient sample SE-211 (48hr) ............................................... 72 
Figure 4.22 Caspase 3/7 activity on AML cell lines upon TRAIL and RO-BIR2 combination 
therapy...................................................................................................................................... 75 
Figure 4.23 Caspase 3/7 activity on patient sample SE211 upon TRAIL and RO-BIR2 
combination therapy................................................................................................................. 75 
Figure 4.24 Western blot analysis of OCI-AML3 after TRAIL and RO-BIR2 combination 
therapy...................................................................................................................................... 77 
Figure 4.25 Cell viability assay on AML cell lines upon RO-BIR2 and Ara-C combination 
therapy...................................................................................................................................... 81 
Figure 4.26 Cell viability assay on AML patient samples upon RO-BIR2 and Ara-C 
combination therapy................................................................................................................. 82 
Figure 4.27 Apoptosis assay of FACS on U-937 cells upon RO-BIR2 and Ara-C treatment . 85 
Figure 4.28 Apoptosis assay on AML cell lines upon RO-BIR2 and Ara-C combination 
treatment .................................................................................................................................. 86 
Figure 4.29 Apoptosis assay on AML patient samples upon RO-BIR2 and Ara-C combination 
treatment .................................................................................................................................. 87 
Figure 4.30 Caspase assay on AML cells and patient sample upon RO-BIR2 and Ara-C 
combination therapy................................................................................................................. 89 
Figure 4.31 Western blot analysis on U-937 cells upon RO-BIR2 and Ara-C combination 
treatment (48hr) ....................................................................................................................... 92 
Figure 4.32 Western blot analysis on SE-211 cells upon RO-BIR2 and Ara-C combination 
treatment (48hr) ....................................................................................................................... 92 
Figure 4.33 Western blot analysis on KG-1 cells upon RO-BIR2 and Ara-C combination 
treatment (48hr) ....................................................................................................................... 93 
Figure 4.35 Top unique regulated genes in U-937 cells .......................................................... 96 
Figure 4.36 ............................................................................................................................... 97 
Validation of top regulated genes on U-937 cells and OCI-AML3 cells ................................ 97 
Figure 4.37 Top canonical pathways on U-937 cells ............................................................. 102 
12 
 
Figure 4.38 Associated network of function of tissue morphology, cell cycle, gastrointestinal 
disease .................................................................................................................................... 103 
Figure 4.39 Associated network of function of hereditary disorder, immunological disease, 
and inflammatory disease ...................................................................................................... 103 
Figure 4.40 XIAP shRNA knock down on AML cell lines ................................................... 106 
Figure 4.41 Cell viability assay on AML cell lines after XIAP shRNA knock down (24hr) 106 
Figure 4.42 Apoptosis assay on KG-1 cells with XIAP shRNA knock down (7 days) ......... 107 
Figure 4.43 Western blot analysis of AML cell lines after XIAP shRNA knock down (72hr)
................................................................................................................................................ 108 





LIST OF ABBREVIATIONS 
 
AML Acute Myeloid Leukemia 
SEER Surveillance Epidemiology and End Results
FAB French-American-British 
WHO World Health Organization 
Ara-C Cytarabine 
APL Acute Promyelocytic Leukemia 
ATRA All-trans-retinoic acid 
FLT3 Fms-Related Tyrosine Kinase 3
HDAC Histone deacetylase 
PLK Polo-like kinase 
TNFR Tumor Necrosis Factor Receptor 
FADD Fas-associated death domain 
BCl-2 B-cell lymphoma 2 
BID BH3 Interacting-Domain Death Agonist 
AIF  Apoptosis Inducing Factor 
SMAC Second Mitochondria-derived Activator of Caspase 
HtrA2 Temperature Requirement Protein A2 
Apaf1 Apoptotic Protease Activating Factor 1 
ATP Adenosine Triphosphate 
IAP Inhibitor of Apoptosis Protein 
XIAP X-linked inhibitor of apoptosis protein 
14 
 
RING Really Interesting New Gene 
BIR Baculovirus Inhibitor of Apoptosis Protein Repeat 
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells 
Ara-CTP triphosphorylated cytarbine  
hENT Human Equilibrative nucleoside transporter  
dCK deoxycytidine kinase  
5NT 5’-nucleotidase  
CDD cytidine deaminase  
IC50 Half maximal inhibitory concentration  
CI Combination index 
Fa Fraction affected 
RIPA Radio-immunoprecipitation assay 
PARP Poly-AD-Ribose Polymerase 
qRT-PCR quantitative real-time PCR  
cDNA complementary DNA  
qRT-PCR quantitative real-time PCR  
GCOS GeneChip Operating Software 
GO Gene Ontology  
GEO Gene Expression Omnibus  
RMA Robust Multichip Average  
IPA Ingenuity Pathway Analysis  
TRC The RNAi Consortium (TRC)  
shRNA Small hairpin RNA 
ANOVA Analysis of variance 
15 
 
SEM Standard error of the mean 
NPM-1 Nucleophosmin  
FLT3 Fms-like tyrosine kinase 3  
ITD Internal tandem duplication 
NUH National University Hospital 
FACS Fluorescence-activated cell sorting 
























1.1 Epidemiology of AML 
1.1.1 AML 
Acute myeloid leukemia (AML) is a blood malignancy in adults which is characterized by an 
infiltration of leukemia cells that expand rapidly in the bone marrow, suppressing normal 
haematopoesis [1]. According to US National Cancer Institute Surveillance Epidemiology 
and End Results (SEER) Stat Fact in 2015, the overall five-year survival rate of AML for 
2005-2011 was only 25.9% (Figure 1.1). What is worse, the incidence has increased 
significantly over the past several decades (Figure 1.2), while there is little improvement in 
therapeutic treatment and overall survival in AML. Recent studies have shown that AML is a 
complex heterogeneous disease driven by multiple chromosomal abnormalities and gene 
mutations, which lead to their different responses to treatment and survival rate [2] [3-6]. 
However, the underlying mechanism of leukemogenesis remains unclear.  
1.1.2 Subtypes of AML 
There are two commonly used classification system for AML, French-American-British 
(FAB) system and World Health Organization (WHO) system.  
The FAB classification system divides AML into eight subtypes, M0-to M7, based on the 
myeloid lineage the leukemia developed from and the degree of maturity (Figure 1.3), which 
was proposed in 1976 [7]. The morphology of AML cells belong to each M0-M7 subtypes is 
quite different and it is easy to be classified under microscope (Figure 1.3, Table 1.1). The 
different subtypes may vary in prognoses and responses to therapy. For instance, AML M3 
subtype, Acute promyelocytic leukemia (APL), had very promising response to drugs as all-
trans-retinoic acid (ATRA) and anthracycline (normally daunorubicin) combination treatment 
[8] [9, 10]. Among the eight FAB subtypes, APL patients had highest chance to be cured [11]. 
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On the other hand, the WHO classification system is a newer classification system, which is 
based on genetically defined subtypes with clear clinical relevance and biological 
underpinnings [12, 13]. WHO system divides AML into 7 subtypes, including AML with 
recurrent genetic abnormalities, AML with myelodysplasia-related changes, therapy-related 
myeloid neoplasms, myeloid sarcoma, myeloid proliferates related to down syndrome, blastic 
plasmacytoid dendritic cell neoplasm and AML not otherwise categorized [7] [13]. For 
instance, AML with recurrent genetic abnormalities, including  AML with translocation 
between chromosome 8 and 21, inversion in chromosome 16, mutation of NPM 1 and so on 
[14], have  important prognostic implication of poor outcomes in AML patients. 
There are more cytogenetic and molecular abnormalities have been identified as prognostic 
markers. Cytogenetic abnormalities of inv(16), t(16;16), t(8;21), t(15;17) are associated with 
better risk of patients with higher long time survival [15] [16], and -5, 5q-, -7, 7q-, 11q23 are 
proved for patient who have poor risk with shorter long time survival [17] [18]. For 
molecular abnormalities, Fms related tyrosine kinase 3 (FLT3) gene is found very commonly 
mutated in AML patients, which is appears to be activated in one third of AML cases, and 
internal tandem duplications (ITDs) of FLT3 happen at a high percentage of AML cases [19]. 
The clinical results indicate that AML patients with FLT3-ITD always had poor outcome, and 
this mutation is widely used as a high risk marker of AML patients [20]. Moreover, small 










Figure 1.1 Five-year survival rate of AML (2005-2011, SEER 2015).  
Grey figures represent patients who have died from AML, and green figures represent 





Figure 1.2 New cases and deaths of AML in US (SEER 2015).   
Green line represents incidence of AML in US during 1975 to 2012, and black line represents deaths. 
All races, both sexes, rates are age-adjusted. 
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Figure 1.3 FAB subtypes of AML, M0-M7.  (Ladines-Castro W, et al. Morphology of 
leukaemias. Rev Med Hosp Gen Méx. 2015) 















A. M0 Undifferentiated acute myeloblastic leukemia 
B. M1 Acute myeloblastic leukemia with minimal maturation 
C. M2 Acute myeloblastic leukemia with maturation 
D. M3 Acute promyelocytic leukemia (APL) 
E. M4 Acute myelomonocytic leukemia 
F. M5 Acute monocytic leukemia 
G. M6 Acute erythroid leukemia 
H. M7 Acute megakaryoblastic leukemia 
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1.1.3Treatment of AML  
Current treatment of AML includes traditional chemotherapy and targeted therapy. 
Chemotherapy is the first-line treatment of AML, which could be divides into two phases, 
induction therapy and consolidation therapy [1]. Induction therapy aims to reduce the 
leukemia cell number to an undetectable level and achieve a complete remission, while 
consolidation therapy’s goal is to prevent patients from relapse and hopefully cure the disease 
[23]. 
1.1.3.1 Chemotherapy 
Cytarabine (Ara-C) and daunorubicin are two widely used chemotherapeutic drugs for the 
induction treatment of all FAB subtypes except M3 subtype. The combination chemotherapy 
regimen using these two drugs is called “7+3”, “7” stands for Ara-C is given 7 consecutive 
days as a continuous IV infusion, “3” stands for daunorubicin is given 3 consecutive days as 
an IV push [23]. For AML M3 subtype, also known as acute promyelocytic leukemia (APL), 
drugs such as all-trans-retinoic acid (ATRA) and anthracycline (normally daunorubicin) are 
used widely [24]. More recently, arsenic trioxide has been shown to be effective in this 
subtype of leukemia [25] [26] . Using these treatments, high cure rates can be achieved for 
APL. 
However, after induction therapy, even when the leukemia cells are undetectable (complete 
remission), relapse still commonly occur as residual disease below the level of detection is 
still present at this stage [27]. That is why consolidation therapy is important to prevent 
relapse [23, 28, 29]. For patients that have good prognosis, additional of several courses of 
consolidation chemotherapy, usually with high doses of Ara-C is adequate [30]. As for 
patients with high risk of relapse, an allogeneic stem cell transplantation is recommended to 
achieve maximal chance of cure [31] [27].  
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1.1.3.2 Target therapy 
Though traditional chemotherapy is widely used for AML treatment, the problem is 
chemotherapy works on all active cells including healthy cells and cancer cells, and always 
leads to a wide variety of very significant side effects, like fatigue, pain, blood disorders, 
nausea, diarrhea, etc [32]. Unlike chemotherapy, targeted therapy exploit molecular 
dependencies in tumor, with relative sparing of normal cells, thus maximizing therapeutic 
effects while minimizing toxicities [33]. 
For example, on AML cells with FLT3 gene mutation, FLT3 inhibitors have good inhibitory 
effect against the leukemic cells especially in combination with chemotherapy [34]. Drugs 
targeting c-Kit leads to good result on c-KIT mutated AML cells [35]. In addition, there are 
many other new drugs targeting other molecular changes in AML cells that are under 
investigation, including histone deacetylase (HDAC) inhibitors, polo-like kinase (PLK) 
inhibitors and auro kinase inhibitors [36]. 
Among the many potential targets in cancer, the apoptotic mechanism is an area worthy of 
exploitation and it is often abnormal. Drugs targeting genes involved in the apoptotic process 
should be investigated and may have therapeutic importance in AML treatment. 
1.2 Apoptosis 
Apoptosis is a mode of cell death which is used by multi-cellular organisms to dispose 
unwanted cells in a variety of settings [37]. It affects organisms’ normal development and 
maintains homeostatic processes [38, 39]. Apoptosis leads to morphological characteristic 
changes including membrane blebbing, cell shrinkage, nuclear fragmentation, chromatin 
condensation and chromosomal DNA fragmentation and finally induces cell death [40] 
(Figure 1.4).  
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In Robert Weinberg’s article “hallmarks of cancer”, they indicate six common hallmarks 
which govern the transformation of normal cells to cancer cells. They include self-sufficiency 
in growth signals, insensitivity to anti-growth signals, tissue invasion and metastasis, 
limitless replicative potential, sustained angiogenesis and evasion of apoptosis [41] (Figure 
1.5). Among them, evasion of apoptosis is an important hallmark of cancer, and inappropriate 
regulation of apoptosis is important in many cancers. 
 
Figure 1.4. Pre-apoptotic cells, early apoptotic cells and late apoptotic cells.  




Figure 1.5. Six hallmarks of cancer.  
Self-sufficiency in growth signals, insensitivity to anti-growth signals, tissue invasion& metastasis, 
limitless replicative potential, sustained angiogenesis and evading apoptosis. [41] 
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Up to now, there are two main pathways leading to the initiation of apoptosis, the 
mitochondrial mediated pathway and the death receptor mediated pathway [42, 43]. The 
death receptor mediated pathway is also called extrinsic pathway, and the mitochondrial 
mediated pathway called intrinsic pathway [44] (Figure 1.6). The common denominator for 
these two pathways is the activation of a family of caspase which ultimately leads to cell 
death. Caspases are a family of cysteine protease that plays an important role in apoptosis 
process. They are ubiquitously expressed in a normal cell in a form of zymogens [45-47]. 
There are 3 subfamilies of caspase based on their substrate preferences: Group 1 (caspase 1, 4 
and 5) is involved in cytokine maturation and inflammation, and Group 2 (caspase 2, 3 and 7) 
and Group 3 (caspase 6, 8, 9 and 10) are involved in apoptosis [46]. Both Group 2 and 3 can 
be further subgrouped into initiator and effector caspases.  
Physiologically, cells are constantly receiving insults both intrinsically and extrinsically, and 
in extreme conditions, these stimuli would induce cell death. After cells receive extrinsic 
apoptotic stimulus through their cell surface receptor, Tumor Necrosis Factor Receptor 
(TNFR), they will undergo oligomerization leading to the formation of a multiprotein 
complex [42]. Through a poorly understood mechanism, this complex will in turn interact 
with Fas-associated death domain (FADD), enabling further recruitment of initiator caspases 
(caspase 8, 9 and 10). The initiator caspases will undergo autoproteolytic processing leading 
to their own activation and they will subsequently process the downstream effector caspases 
(caspase 3, 6 and 7) and pro-apoptotic B-cell lymphoma 2 (BCl-2) family protein [48]. In the 
intrinsic pathway, the activated caspase 8 will process BH3 Interacting-Domain Death 
Agonist (BID), inducing a conformational change on BCl-2 protein and leading to 
mitochondrial permeabilization [45, 46]. Upon permeabilization, several pro-apoptotic 
proteins will be released into the cytosol including cytochrome C, Apoptosis Inducing Factor 
(AIF), Second Mitochondria-derived Activator of Caspase (SMAC) or Omi/High 
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Temperature Requirement Protein A2 (HtrA2) [49-55]. The cytochrome C will further form a 
protein complex with Apoptotic Protease Activating Factor 1 (Apaf1) and Adenosine 
Triphosphate (ATP) and bind to caspase 9 causing its activation. The activated caspase 9 will 
mark the initiation of the downstream caspase cascade causing further proteolytic activation 
of effector caspases (caspase 3 and 7), which will in turn act on multiple substrates and ends 
in the eventual apoptosis [42, 43, 45, 46, 48-50, 52-54, 56-59]. However, it has been reported 
that there are 8 families of protein that could inhibit the activity of these enzymes, termed the 
Inhibitor of Apoptosis Proteins (IAPs), and the best characterized among them is XIAP, 
which is the only IAP with a direct inhibitory activity on both initiator and effector caspases 
[43, 47, 49-54, 56, 58, 60]. 
 
Figure 1.6 Extrinsic pathway and intrinsic pathway of apotosis. 




1.3 XIAP in AML 
XIAP consists of C-terminal Really Interesting New Gene (RING) finger with an intrinsic E3 
ubiquitin ligase activity, while its N-terminus has three tandem repeats [49] [61] (Figure 1.7). 
Since it was first studied in Baculovirus, the tandem repeat is called Baculovirus Inhibitor of 
Apoptosis Protein Repeat (BIR) and it is evolutionary conserved across different species [53]. 
Each of these domains has its own function. For a long time, the BIR1 domain was thought to 
have no function at all. But in 2007, it was reported to induce nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) activation, allowing cancer cell survival during 
pathological conditions [58]. This further emphasizes the potential value of targeting XIAP as 
a therapeutic cancer treatment. The linker region, together with BIR2 domain, inhibits the 
activity of effector caspase 3 and 7 through exclusive binding affinity, while the BIR3 
domain inhibits the activity of initiator caspase 9 by preventing its homodimerization [43, 47, 
49-55, 58]. Due to its inhibitory activity on a family of caspase proteins exerted by both 
linker-BIR2 and BIR3 domains, which is suspected to be the cause of the block in apoptosis 
of cancer cell, designing a drug inhibiting XIAP activity provides an enticing prospect in 
priming the cancer cell to its own cell death program [62].  
 
 
Figure 1.7. The structure of XIAP. 
XIAP includes three BIR domains (BIR1, BIR2, BIR3), an E3 uniquitin ligase activity (UBA) and a 




1.4 Drug discovery of XIAP inhibitors 
XIAP blocks a substantial portion of the apoptosis pathway and is an attractive target for 
novel therapeutic agents for the treatment of malignancy [63]. In AML, it has been reported 
that XIAP has high expression and contributes to chemoresistance [64], and in AML patients, 
there is a association of high XIAP levels with low overall survival [65].There are two 
regions in XIAP that have a direct inhibitory effect on caspases, the BIR3 and BIR2 domains 
[66]. Table 1 summarizes the current status of the pre-clinical development of BIR2 and 
BIR3 small molecule inhibitors [67] [68] [69] [55] [47] [70]. It is clear that most research 
focus BIR3 inhibitors, with relatively limited progress on inhibtors against the BIR2 domain 
[71]. Herein we investigated the effect of a newly developed BIR2 inhibitor, RO-BIR2, on 
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and brain  
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Nikolovska-
Coleska, Z., et al. 
(2004) 
Embelin University of 
Michigan, USA 
BIR3 Prostate Preclinical
Sun, H., et al. 
(2006) 
SM131 University of 
Michigan, USA 
BIR3 Breast  Preclinical
Zobel, K., et al. 
(2006) 
Compound 8 Genentech, USA BIR3 Breast and 
melanoma 
Preclinical
Flygare, Beresini et 
al. (2012) 
GDC-0152 USA BIR3 Breast Preclinical
Schimmer, A.D., et 
al. (2004) 
TP-1396-12 Burnham Institute, 
USA 




Wu, T.Y., et al. 
(2003) 
TWX 024 Novartis BIR2 Colorectal Preclinical
 
Table 1.2 Drug discovery of XIAP BIR3 and BIR2 Inhibitors  
 
BIR3 inhibitors re more studied, but progresson on inhibitors against the BIR2 domain were limited. 
[67] [68] [69] [55] [47] [70]  
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There is a great need to discover novel therapeutics for AML as current treatment has not 
changed in the last few decades and overall outcome is still poor. Chemotherapy such as Ara-
C drug is a standard treatment method for AML patients, however a number of AML patients 
gain chemoresistance. Current research states that factors that reduce the intracellular 
concentration of triphosphorylated cytarbine (Ara-CTP), which is the active form of Ara-C, 
may induce chemoresistance in AML [72]. These factors include key genes of Ara-C 
metabolic pathway, such as human Equilibrative nucleoside transporter (hENT), 
deoxycytidine kinase (dCK) and 5’-nucleotidase (5NT) and cytidine deaminase (CDD) [72]. 
Besides the chemoresistance, severe side effect is another problem of chemotherapy. 
Targeting therapy is a more promising way to maximizing therapeutic effects while 
minimizing toxicities, among which, targeting the apoptotic pathway is relatively under-
explored in AML despite ample evidence that it is deregulated in AML. With this in mind, 
we set out to achieve the following objectives in this thesis. 
2.1. To determine the therapeutic efficacy of the drug RO-BIR2 
As we know, AML has an increasing incidence in the past century. However, the treatment 
for AML has not change. Many studies have shown that inability to undergo apoptosis is one 
of the hallmarks of cancer, and drugs targeting XIAP may be a new therapeutic treatment for 
AML [73, 74].  XIAP consists of three BIR domains. Research on XIAP inhibition has 
focused so far mainly on targeting BIR3, while efforts targeting BIR2 are relatively limited 
[75]. In addition, drugs targeting BIR3 still have some side effects. It is therefore our hope 
that a novel BIR2 inhibitor may have a better profile of efficacy and toxicity.   
RO-BIR2 is a newly developed drug targeting the BIR2 domain of XIAP. At the molecular 
level, inhibiting the BIR2 domain, which directly acts on the effector caspases at the more 
distal end of apoptosis machinery, in theory, will induce apoptosis more effectively than 
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inhibiting BIR3 domain which only acts on the initiator caspase [76, 77]. Effector caspases 
have also been shown to enable the release and activation of initiator caspase. So by 
attenuating the effector caspase through BIR2 inhibition, it will generate a positive apoptosis 
feedback loop. So the BIR2 inhibitor may be a promising targeted drug to reactivate 
apoptosis and kills AML cells. 
In this project, we aim to determine the efficacy of the RO-BIR2 drug on both AML cell lines 
and AML patient samples. We also hypothesize that by triggering apoptosis through either 
TRAIL or chemotherapy, the cells will be even more susceptible to XIAP BIR2 domain 
inhibition with RO-BIR2. This may be potentially more useful clinically as we can build on 
the usual backbone of drug (Ara-C) that is utilized in the treatment of AML.  
2.2. To identify the underlying molecular mechanism of RO-BIR2 
AML is divided into eight subtypes (M0-M7) according to FAB classification system. 
Different subtypes vary in prognosis and therapeutic response in the clinic. It is of interest to 
study the potential differential effect of RO-BIR2 and combination therapy in different AML 
cells, and understand the underlying mechanism of response and resistance.  
2.3. To investigate the role of XIAP in modulating cell death in AML 
As RO-BIR2 is an XIAP BIR2 inhibitor, we will also investigate in detail the impact on the 
apoptotic pathway and apoptosis in cells upon RO-BIR2 treatment and combination therapy. 
It is worthy of analysing the correlation of XIAP expression level and survival analysis on 
AML patients, how the RO-BIR2 treatment and combination therapy with TRAIL or Ara-C 
effect the cell caspase activity, apoptotic proteins level change and cell death, how XIAP 
plays a role in inducing cell death on AML cells and patient samples, and finally refer to 
other XIAP inhibitors to have a better understanding of XIAP and apoptosis pathway. 
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3.1 Cell culture  
OCI-AML2 and OCI-AML3 cell lines were obtained from DSMZ (Braunschweig, Germany). 
HL-60, MV4-11, KG-1 and U-937 cell lines were obtained from ATCC (Manassas, VA).  
OCI-AML2 and OCI-AML3 cells were cultured with 80% MEM-α (GIBCOTM ,SG) with the 
addition of 20% FBS (JRHBioscience Inc, SG) at a density of 0.5-2×106 cells/ml in a humid 
incubator with CO2 at 37 °C. HL-60, MV4-11, KG-1, and U-937 cells were cultured with 
RPMI 1640 (Invitrogen) supplemented with the addition of 10% at density of 0.5-1×106 
cells/ml in a humid incubator with CO2 at 37 °C.  
AML patient samples, AD330, AD448, AD450 and SE211 were obtained from National 
University Hospital (NUH) in Singapore and cultured with RPMI 1640 added 10% FBS and 
10 ng/ml cytokines (FLT-3 ligand, IL-3, CSF, GM-CSF, TPO from Peprotech, USA) at 
density of 0.5-2×106 cells/ml in a humid incubator with 5% CO2 at 37°C. These AML patient 
samples were obtained after informed consent and the collection of patients sample for 
research was approved by the institution’s review board. 
SW-620 cell line was obtained from ATCC and cultured with DMEM (Biowest, USA) added 
10% FBS in humid incubator with 5% CO2 at 37°C. 
3.2 Freezing and thawing of cultured cell lines 
To freeze cell lines, cells were centrifuged at 1200 rpm for 3 minutes, and after that the 
supernatant was discarded. The cell pellets were resuspended with freezing media with 5% 
DMSO at a concentration of 1x106/ml, and then aliquoted into cryvials and placed in a Mr. 
Frosty cyclinder which was filled isopropanol. After at least 24 hours incubation in -80 °C 
freezer, the cryovials were transferred into a liquid nitrogen tank for long term storage. 
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To thaw frozen cells, took out a cryovial from liquid nitrogen tank, put them on dry ice and 
thaw it rapidly inside a 37°C water bath. Then added the thawed cells into 5 ml media in a 15 
ml falcon tube and resuspended it, then centrifuged the cells at 1200 rpm for 3 minutes and 
discarded the supernatant. Added fresh media to the cell pellet, resuspended it, seeded it into 
a T25 flask and placed the flask in humid incubator with 5% CO2 at 37°C.  
3.3 Cell viability assay 
Cell viability was monitored by using the CellTiter-Glo assay (Promega, Madison, WI). 
Three drug compounds were used in cell viability assay, RO-BIR2, TRAIL and Ara-C. RO-
BIR2 is a BIR2 XIAP inhibitor, which was obtained from a particular pharmaceutical 
company (due to the agreement, the name of the company couldn’t be shown). TRAIL and 
Ara-C were obtained from R&D System (USA), and these two drugs were used in 
combination with RO-BIR2 in this project. Both single drug and combination drug treatments 
were used for cell viability assay. 
Before drug treatment, all cells were cultured according to the vendor’s instructions. For cell 
viability assay, 5,000 cells in 100 µl media were seeded for adherent cell (i.e. SW-620) and 
10,000 cells in 100 µl for suspension cell (i.e. OCI-AML2) in 96-well transparent plates. 
After 24 hours cells were treated with drug compounds in triplicates at different 
concentrations for 48 hours. Each well was added 100 µl CellTiter-Glo reagent and mixed, 
and the mixture of cells and reagent were transferred to 96-well white plates. Then the white 
plates were centrifuged at a low speed (300 rpm) for 5 minutes to removes the air bubbles in 
the mixture, and after 10 minutes incubation the luminescence was measured. The cell 
viability changes were calculated based on the luminescence readings. 
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3.4. Half maximal inhibitory concentration (IC50) and Combination index (CI) 
calculation 
The IC50 and CI of drugs were determined by cell viability assay and calculated with 
CompuSyn software (Combo Syn, Inc. USA). The CompuSyn software was used to analyse 
drug’s dose-effect relationships on AML cell lines and patient samples. The CI was applied 
to quantitatively describe synergism defined as a greater-than-additive effect from a 
combination of two agents (CI<1), antagonism as a less-than-additive effect (CI>1), and as an 
additive effect (CI = 1). The CI values were calculated according to the levels of growth 
inhibition (Fraction affected, Fa) by each agent individually and combination different drug 
compounds.  
3.5 Caspase3/7 activity assay 
The reagent caspase-Glo ® 3/7 assay was obtained from PROMEGA. For caspase 3/7 
activity assay, 5,000 cells in 100 µl media were seeded for adherent cell (i.e. SW-620) and 
10,000 cells in 100 µl media for suspension cell (i.e. OCI-AML2) in 96-well transparent 
plates. After 24 hours cells were treated with drug compounds and incubated for 24 hours. 
Then each well was added 100 µl caspase-Glo 3/7 reagent and mixed, and the mixture of 
cells and reagent were transferred to 96-well white plates. The white plates were centrifuged 
at a low speed (300 rpm) for 5 minutes to remove the air bubbles in the mixture, and after 30 
minutes incubation the luminescence was measured. The caspase 3/7 activity changes were 




3.6 Protein extraction and Bradford protein assay 
To extract proteins, cells were harvested and lysed with radio-immunoprecipitation assay 
(RIPA) buffer (20 mM HEPES at pH 7.4, 1% Triton X-100,150 mM NaCl, 1 mM EDTA, 1 
mM EGTA) with addition of 1×protease inhibitor and 1×phosphatase inhibitor. After 
incubation on ice for 30 minutes (vortex for 10 seconds every 10 minutes), the cell lysate 
were centrifuged at 14,000×g for 15 mins at 4°C. Finally, the supernatant were transferred to 
1.5 ml empordoff tubes and stored in -80°C fridge for future use. 
Total protein concentrations were determined by using the Bradford protein assay (Bio-Rad 
Laboratories Inc). Normally the protein concentrations were assayed in duplicate. In a 96-
well transparent plate, the protein standard was prepared by a linear range of 10 µl BSA (1 
mg/ml BSA diluted with H2O to 0.5 mg/ml, 0.25 mg/ml, 0.125 mg/ml , 0.0625 mg/ml and 
0.03125 mg/ml), proteins samples for testing were also diluted with water(1 µl sample in 9 µl 
H2O), and then 200 µl Bradford dye were added into each well. After incubated in room 
temperature for 5 minutes, read the absorbance at 595 nM. The absorbance readings were 
used to calculate the concentration of protein samples.  
3.7 Western Blot  
Primary antibodies including caspase 3, caspase 7, caspase 8, caspase 9, Bax, Bad, BCl2 and 
cleaved Poly-AD-Ribose Polymerase (PARP) antibodies were purchased from Cell Signaling 
Technology (Beverly, MA). XIAP antibody was purchased from R&D systems. Actin 
antibody and secondary antibodies including goat anti- mouse, goat anti-rabbit antibodies 
were purchased from Santa Cruz Biotechnology. The images were captured by Konica 
Medical SRX-101A Medical Film Processor (Konica Minolta Medical &Graphic, Inc, USA). 
Before performing western blot analysis, prepare loading protein samples by adding an equal 
volume of 2×laemmli sample buffer to the cell lysates. After boiled at 95°C for 5 minutes and 
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cooled to room temperature and centrifuge, the cell lysates could be aliquoted and stored at -
20 °C for future use. 
SDS-PAGE gels of 10%-14% were used to separate proteins. Equal amounts of proteins were 
loaded to the wells of the gels, along with the molecular weight markers. Run the gel at 75 V 
for about 20 minutes until all the samples have reached the resolving gel, then increase the 
voltage to 100-150 V (depends on the percentage of the gel). After the desired resolution has 
been achieved, remove the stacking gel, and soak the resolving gel in transfer buffer. Then 
assemble the transfer sandwich and make sure no air bubble was trapped in the sandwich. Put 
the sandwich cassette in the transfer tank filled with transfer buffer and place it in the cold 
room, and the transfer process would be done after electrophoresis at 300 mA for 1.5 hours. 
Then the membranes were removed from the cassette and soaked in blocking buffer (5% non 
fat dry milk in PBS-Tween buffer) in a square dish for 1-2 hours at room temperature on a 
rocking platform. Then the membranes were incubated in primary antibody (1:1000 dilutions 
with PBS-Tween buffer) at 4 °C solution overnight. After rinsed 3-5 times for 5 minutes with 
PBS-Tween buffer, the membranes were incubated with secondary antibody for 1 hour at 
room temperature. Rinse the blot again and apply the chemiluminescent substrate to the blot 
and capture the chemiluminescent signals by using Konica Medical SRX-101A Medical Film 
Processor.   
3.8 Flow cytometry analysis of apoptosis assay 
Cells were cultured in 6-well plates in the presence of different concentrations of BIR2 XIAP 
inhibitor RO-BIR2, TRAIL or Ara-C drugs. After 48 hours incubation in a humid incubator, 
5x105 - 1x106 cells were counted and washed with 1x PBS (1200 rpm for 3 minutes) twice. 
The cell pellets were resuspended with 100 µl 1x binding buffer, and stained with1.5µL FITC 
Annexin V (BD PharmingenTM )and 1µl sytox blue (Invitrogen) for 15 minutes in the dark. 
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Add 400 µl 1x binding buffer afterwards, and filter the mixtures into 5 ml BD falcon tubes. 
The samples were kept on ice and away from light, and immediately analysed by using LSRII 
flow cytometer (BD Biosciences, SG) and Flowjo software (TreeStar Inc, USA). 
3.9 RNA extraction 
Total RNA were isolated from various cell lines using RNeasy mini kit (Qiagen, SG). Cells 
were harvested, washed by PBS, and disrupted by adding buffer RLT. An equal volume of 70% 
ethanol was added to the homogenized lysate and mixed well by pipetting. The mixture of 
nucleic acids and ethanol was transferred to the RNeasy spin column to allow RNA binding. 
Afterwards the column was washed once with 750 μl RW1 buffer and twice with 500 μl RPE 
buffer and centrifuged at 8,000 rcf for 30 seconds and the flow-through was discarded. 
Finally, the spin column was placed in a new 1.5 ml collection tube and 30-50 μl RNAse-free 
water were added to the column membrane, and centrifuge for 1 minute at 8,000 rcf to elute 
the RNA. The RNA’s concentration was assessed by using Nanodrop ND-1000 (Thermo 
Scientific, SG). 
3.10 Reverse transcription and quantitative real-time PCR (qRT-PCR) 
To convert RNA samples into single-stranded complementary DNA (cDNA) samples, 
ReadyScript™ cDNA Synthesis Mix (Sigma Aldrich, SG) was used. The initial step was 
preparation of 1 μg of RNA samples in nuclease-free water in 96-well plate sitting on ice. 4 
μL of ReadyScript cDNA synthesis Mix and a variable volume of nuclease-free water were 
added to the RNA samples to make sure the total volume of the mixture is 20 μl. Afterwards 
the 96-well plate was subjected to PCR amplification using thermo cycler at 5 minutes at 
25°C, 30 minutes at 42°C, 5 minutes at 85°C, and followed by holding at 4°C. The cDNA 
products can be diluted with nuclease-free water and stored at -20°C. 
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To perform quantitative real-time PCR (qRT-PCR), cDNA samples obtained above were 
further diluted in 5 times dilution factor, followed by dispensing into a 96-well reaction plate 
(Thermo Fisher MicroAmp® Fast Optical, SG). A master mix of 10μM gene-specific primer, 
2X KAPA SYBR® FAST qPCR (Kapa Biosystems, SG) and nuclease water was prepared 
and dispensed into each individual well of the 96-well plate. PRISM 7500 Fast Real-Time 
PCR system (Applied Biosystems, SG) was used to amplify and quantify the samples.All 
reactions were designed in triplicate using the specific gene primers (Appendix 1) and 
GAPDH level was used as an internal control. 
3.11 Microarray 
U-937 and OCI-AML3 cells were treated with DMSO (as control) and 2 μM RO-BIR2 for 
24hours (biological duplicates), then the total RNA was isolated from treated cells using 
RNeasy mini kit according to manufacturer’s instruction. Nanodrop ND-1000 was used to 
check the RNA quantity and quality. Human Gene 1.0ST array (Affymetrix, Santa Clara, 
USA) was used for gene expression profiling. The data analysis was done by GCOS 
(GeneChip Operating Software, Affymetrix, USA) and GeneSpring (Agilent, SG). Then, a 
two-fold filter was applied to select genes that were two times changes than control. Gene 
Ontology (GO) was used to do the further functional profiling. 
3.12 Data preprocessing of Affymetrix microarray gene expression and survival analysis 
Microarray data of human AML on Affymetrix U133A or U133Plus2 platforms were 
downloaded from Gene Expression Omnibus (GEO), and on each dataset Robust Multichip 
Average (RMA) normalization was performed. The normalized data was combined for each 
disease and subsequently standardized using ComBat to remove batch effect. The dataset of 
human acute myeloid leukemia consists of 1,149 samples from 5 cohorts, including 
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GSE10358 (n = 275), GSE12417 (n = 242), GSE14468 (n = 65), GSE16015 (n = 107), and 
GSE6891 (n = 460). Among these 1,149 samples, 333 AML has survival information.  
The association of XIAP gene expression with overall survival was assessed using Kaplan-
Meier analysis. AML patients were segregated into XIAP-high or XIAP-low based on 
median gene expression level. The overall survival-XIAP gene expression association was 
also looked into within each FAB subtypes. 
3.13 Gene Ontology analysis and Ingenuity Pathway Analysis (IPA) 
Refer to the microarray data, Gene Ontology (GO) and Ingenuity Pathway Analysis (IPA) 
was used to analyze the underlying pathway and functional networks to investigate the 
mechanism of how RO-BIR2 responses differently on U-937 and other AML cells. The 
downregulated geneset was imported into IPA software for analysis, and gene network, 
biological function, upstream and downstream regulator analysis enriched in the geneset were 
obtained for further experiment. 
3.14  XIAP shRNA knock down and NEON transfection 
The RNAi Consortium (TRC) lentiviral XIAP shRNA (Open Biosystem, Thermo Scientific, 
SG) were used to knock down XIAP in AML cell lines by NEON transfection system 
(Invitrogen, SG). The transfection condition was 1250 voltage, 10 ms, 3 pulses. After 
transfection, qRT-PCR and western blot were used to check the knock down efficiency. 
3.15 Statistical analysis 
The experimental results presented in the figures in the following result part were 
representative of duplicate or triplicate observations. The data were presented as the mean 
values ± Standard error of the mean (SEM). Comparisons between two groups were 
evaluated by t test. Multiple comparisons among more than two groups were evaluated by 
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two-way Analysis of variance (ANOVA). And values of *P ≤ 0.05 were considered to be 



















4.1 Expression of XIAP on AML cells and patient samples, AML subtypes overall 
survival  
It has been reported that XIAP is highly expressed in AML cells and contributes to 
chemoresistance [64], and there is a correlation of high XIAP protein levels with poor overall 
survival in AML patients [78]. In this project, we downloaded microarray data of human 
AML on Affymetrix U133A or U133Plus2 platforms from GEO, and use Kaplan-Meier 
analysis to investigate the association of XIAP gene expression with overall survival rate. As 
illustrated in the section 3.12, the dataset of human AML downloaded from GEO consists of 
1,149 samples, among which 333 AML samples have survival information.  
The analysis of XIAP expression level among these 1,149 samples was grouped by two 
classification methods, FAB classification system and karyotypes classification system. And 
the subtype-XIAP expression curve indicated there was no significant difference of XIAP 
expression amongst the different subtypes (Figure 4.1). 
Afterwards, the investigation was performed on whether the overall survival had some 
correlation with XIAP expression level. These 333 AML patient samples with overall 
survival data were segregated into XIAP-high or XIAP-low based on median gene expression 
level, and we looked into the overall survival-XIAP gene expression association by Kaplan-
Meier analysis. Different to some current clinical findings which has published, our results 
revealed that XIAP-low and –high groups didn’t make a significant difference on overall 
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Figure 4.1 XIAP expression level among AML subtypes 







Figure 4.2 Correlation of XIAP level and AML patients overall survival 
XIAP-low and XIAP-high groups overlapped on percentage survival. The overall survival decreases 
very rapidly, rare patients survived after 60 months. This result is consistent with SEER Stat Fact 
2015, which reported the 5-year survival of AML around the world is only 25.9 (SEER, 2015). 
 
FAB subtypes (n=1,149) 
Karyotypes (n=1,149) 




Low: < median 
High: > median 
HR=0.9404     p=0.668 
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However, among each subtypes, the correlation of XIAP expression and overall survival was 
complicated. These 333 AML samples were divided into eight subtypes (MO-M7) according 
to FAB classification system, based on the myeloid lineage developed from and the degree of 
maturity (M0, n=17; M1, n=93; M2, n=102; M3, n=6; M4, n=71; M5, n=37; M6, n=9; M7, 
n=0) (Figure 1.3).  
The analysis indicated that only in AML M2 subtype, XIAP-high group (blue line) had 
signification correlation (p<0.05) with poorer overall survival compared to XIAP-low group 
(red line). The survival rate decreased rapidly to nearly 0 since 20 months since diagnosed 
with AML, while XIAP-low group still had some survivors until 60 months (Figure 4.3). 
Among other AML subtypes (M0, M1, M3, M4, M5, M6), the survival rate results had little 
difference between XIAP-low and XIAP-high groups (Figure 4.3). This result suggested 
XIAP was probably an important marker for AML M2 subtype in clinic prognosis, and XIAP 
inhibitors would be hopefully practical on XIAP-high patients. Further research on AML M2 
subtype is considerable, and it is quite interesting to study the underlying mechanism of this 














Figure 4.3 Overall survival-XIAP gene expression associations among AML FAB subtypes 
The blue line represents XIAP-low group, and the red line represent XIAP-high group. In AML M2 
subtype, there is a significant correlation of high XIAP expression level with poor survival rate 




 M0 Overall survival (n=17)         M1 Overall survival (n=91)              M2 Overall survival (n=102) 
HR=0.7501                                    HR=0.1408                                         HR=0.5815 
p=0.668                                         p=0.1857                                             p=0.0401 
 M3 Overall survival (n=6)         M4 Overall survival (n=71)              M5 Overall survival (n=37) 
HR=0.1353                                   HR=1.213                                           HR=1.076 




Low: < median 
High: > median 
 M6 Overall survival (n=9)          
HR=1.137           
p=0.8985             
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4.2 Positive control of the BIR2 inhibitor drug RO-BIR2 on SW-620 cells 
RO-BIR2 is a BIR2 inhibitor drug targeting XIAP BIR2 domain. This drug was designed to 
selectively targeting BIR2 domain and activating caspase 3 and caspase 7, and had 
advantages over XIAP BIR3 and cIAP BIR2/3 inhibitors [76]. The RO-BIR2 drug had been 
tested by the company on a few colorectal cancer cells including SW-620 cell line, and the 
result showed monotherapy of RO-BIR2 had little effect while combination with TRAIL led 
to high synergy. We therefore first confirm the activity of the compound on SW-620. 
The BIR2 inhibitor drug RO-BIR2 was subjected to three times dilution, from 10,000 nM, 
3333.33 nM, 1111.11 nM, 370.37 nM to 41.75 nM (DMSO was used as control), added to 
SW-620 cells and incubated for 48 hours. Then Cell viability assay was used to analyze the 
cell viability changes. The result revealed RO-BIR2’s single treatment, even at a high dose of 
10,000 nM, had little effect on SW620 cells’ inhibition of proliferation (Figure4.4 A). 
On the other hand, TRAIL had dose-dependent effect on SW620 cells (Figure 4.4B). With 
doses of 0, 0.52 ng/ml, 1.85 ng/ml, 5.56 ng/ml, 16.67 ng/ml to 50 ng/ml TRAIL treatment, 
the cell viability percentage of SW620 decreased from 100% to nearly 60% (Figure 4.4B, 
black line). Since SW-620 cells were resistant to RO-BIR2 drug, even at a high dose of 10 
μM, the inhibition of proliferation effect was still low, thus we planned combination 
treatment of increasing dose of TRAIL with constant 5 μM or 10 μM RO-BIR2 on SW-620 
cells. The inhibition of proliferation effect was much better than monotherapy of RO-BIR2, 
that the percentage of viable cell decreased below 50 rapidly, and two-way ANOVA 
indicated combination treatment was significantly different from single treatment samples 
(Figure 4.4B).  
CompuSyn software was used to analyze drug’s dose-effect and combination treatment. CI 
was applied to quantitatively describe the drug combination effect to three types, synergism 
(CI<1), antagonism (CI>1) and additive effect (CI=1). As the dose-effect curve and 
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combination index plot showed, RO-BIR2 and TRAIL combination treatment resulted in 
highly synergistic effect (CI<0.1) (Figure 4.5 A, B, C).  
In summary, RO-BIR2 monotherapy had limited effect on SW620 cells, while combination 
with TRAIL led to high synergistic effect compared to TRAIL or RO-BIR2 single treatment 
(Figure 4.4, Figure 4.5). This result confirmed the efficacy of RO-BIR2 which had been 
stated by the company. We therefore proceeded to test the RO-BIR2 drug on our cells of 
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Figure 4.4. Monotherapy and Combination therapy on SW-620 cells 
 
A. RO-BIR2 single treatment on SW-620 cells (48hr), one way ANOVA was used as statistical 
analysis and all the data in the graph bars represented ± SEM; p-value ≤ 0.0001.   
B. RO-BIR2 and TRAIL combination treatment on SW-620 cells (48hr), light grey bars represent 
TRAIL single treatment, dark grey bars represent combination treatment of 5 μM RO-BIR2 with three 
times increased dose of TRAIL, black bars represent combination treatment of 10μM RO-BIR2 with 
three times increased TRAIL. Two way ANOVA was used as statistical analysis and all the data in 




     
      A. Dose-Effect Curve of RO-BIR2 and TRAIL combination on SW620 cells             
                                          
   
B.  Combination Index Plot RO-BIR2 and TRAIL combination on SW620 cells             
 
Dose TRAIL Dose BIR2 Effect CI 
50.0      5000 0.98      0.07116
16.67      5000 0.92      0.05979
5.56      5000      0.68      0.05853
C.  CI value for Non-Constant RO-BIR2 and TRAILCombination on SW620 cells 
    
Figure 4.5 CI calculation of RO-BIR2 and TRAIL combination on SW620 cells 
A. Dose-effect curve of RO-BIR2+TRAIL combination treatment on SW620 cells; B. Combination 
index plot of RO-BIR2+TRAIL combination treatment on SW620 cells; C. CI data for RO-BIR2 and 
TRAIL combination treatment on SW620 cells (CI<1, synergistic).  
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4.3 Monotherapy of the BIR2 inhibitor drug RO-BIR2 on AML cells and patient 
samples 
Several AML cell lines and AML patient samples were chosen to be tested by RO-BIR2 drug. 
AML cell lines included U-937, KG-1, OCI-AML2, OCI-AML3, MV4-11 and HL-60 cells, 
and AML patient samples involved AD450, AD330, AD448 and SE211 cells, which were 
obtained from National University Hospital of Singapore with approval. 
These six AML cell lines belonged to different AML FAB subtypes as listed in the following 
table (table 4.1). Both OCI-AML2 and OCI-AML3 cell lines belonged to M4 subtype 
leukemia, OCI-AML3 had a mutation in the nucleophosmin (NPM-1) gene associated with a 
good prognosis [3, 80], and OCI-AML2 was NPM-1 widetype. MV4-11 cell line belonged to 
FAB M5 type leukemia, which had been exhibited FLT3-ITD which associated with a poor 
prognosis [81, 82].  
Though AML cell lines belonged to different FAB subtypes, the XIAP expression levels 
revealed by qRT-PCR and western blot showed slight differences among most of the samples, 
except U-937 cells, which had much lower XIAP expression level compared to other AML 
cell lines [Figure 4.6A, Figure 4.6B]. For AML patient samples, AD370 cells’ XIAP 
expression was apparently higher.  Interestingly, as described in the following parts, the 




FAB subtypes AML cell lines 
M1 KG-1 
M2 HL-60 
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Figure 4.6 XIAP expression level on AML cell lines and AML patient samples 
 
U-937, OCI-AML2, OCI-AML3, HL-60 and KG-1 are AML cell lines. SE211 and AD370 are AML 
patient samples obtained from NUH. 
  
U-937     OCI-AML2 OCI-AML3 HL-60 KG-1    SE211     AD370 
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4.3.1 Cell viability assay  
4.3.1.1 Cell viability assay on AML cells 
To test the effect of RO-BIR2 drug, cell viability assay was used. RO-BIR2 drug was treated 
on six AML cells from the concentration of 10 μM to 0.39 μM (1.5 times dilution), DMSO 
was used as control, and after drug treatment the cells were incubated in a humid incubator 
for 48 hours. Celltitre-Glo luminescent cell viability assay was used to analyze the inhibition 
of the cell proliferation of RO-BIR2.  
Interestingly, U-937 cells, which had the lowest expression of XIAP, responded to RO-BIR2 
drug differently. Different from other AML cell lines (MV4-11, OCI-AML2, OCI-AML3, 
KG-1 and HL-60) which showed very resistant responses upon 48 hours’ RO-BIR2 drug 
treatment, U-937 cells had dose-dependent effect. However, the inhibition of cell 
proliferation effect of RO-BIR2 drug on U-937 cells was not potent, that only at a high dose 
of the drug (10 μM), the cell viability reduced to nearly 50% (Figure 4.7 A). The dose-effect 
curve analyzed by CompuSyn software showed, the IC50 of RO-BIR2 drug on U-937 cells 
was 17818.1nM, which was relatively very high (Figure 4.8). 
On the other hand, the other five AML cell lines which belonged to different FAB subtypes, 
the monotherapy of RO-BIR2 had similar affection, that all of them were much less sensitive 
to the drug compared to U-937 cells (Figure 4.7 B, C, D, E, and F). The mechanism of this 
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Figure 4.7 Cell proliferation assay analysis of RO-BIR2 monotherapy on AML cell lines 
 
A. U-937; B. MV4-11; C. OCIA-ML2; D. OCI-AML3; E. KG-1; F. HL-60.  






Figure 4.8 Dose-effect curve of RO-BIR2 monotherapy on U-937 cells (48hr) 
CompuSyn software was used to analyze RO-BIR2’s dose-effect on U-937 cells. The IC50 of RO-








4.3.1.2 Cell viability assay on AML patient samples 
Drug test on patient samples was very important in the process of drug discovery [83]. In our 
project, four AML patient samples, AD450, AD330, AD448 and SE211 cells were obtained 
from NUHS with approval. The result of patient samples upon monotherapy of RO-BIR2 
drug was quite similar to U-937 cells, that all of them responded to the drug dose dependently 
with a relatively high IC50 (Figure 4.9, Figure 4.10) 
Among the four AML patient samples, AD450 was the most resistant sample to RO-BIR2 
drug, with the IC50 as high as 42,655.7 nM (Figure 4.10 B). Other AML patient samples’ 
IC50 was around 10,000 nM to 20,000 nM (AD448, 10032.8 nM; AD330, 16289.5 nM; 
SE211, 10944.7 nM) (Figure 4.10 A, C, D). 
 
Above all, the monotherapy of RO-BIR2 had limited affections on both AML cell lines and 
AML patient samples. Most of the AML cell lines were quite resistant to RO-BIR2 that even 
at a very high dose of drug (up to 10 μM), the inhibition of proliferation was very limited 
(below 5%). U-937 cells and all the AML patient samples were less sensitive and resulted in 
dose-dependent effect upon 48 hours’ drug treatment, however, the IC50 was relatively high 
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Figure 4.9 Cell proliferation assay analysis of RO-BIR2 monotherapy on AML patient samples 
A. AD448; B. AD450; C. AD330; D. SE211. In each bar graph, one way ANOVA was used as 
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Figure 4.10 Dose-effect curve of RO-BIR2 monotherapy on AML patient samples (48hr) 
A. AD448; B. AD450; C. AD330; D. SE211. CompuSyn software was used to analyze RO-BIR2’s 
dose-effect on these four AML patient samples. The IC50 of RO-BIR2 on AD448 was 10032.8nM, 
















4.3.2  Apoptosis assay by FACS  
Apoptosis assay by FACS was used to detect early apoptotic and late apoptotic cell 
population after drug treatment [84]. FTIC Annexin V and sytox blue antibodies were used to 
stain RO-BIR2 treated AML cells and patient samples. Annexin V (+) sytox blue (-) and 
Annexin V(+) sytox blue (+) population represent cells undergoing apoptosis, and Annexin 
V(-) sytox blue (-) population represent viable cells. 
The following FACS figures displayed apoptotic cell population of RO-BIR2 treated cells at 
the concentration of 625 nM, 1250 nM, 2500 nM and 5000 nM, DMSO was used as control 
(Figure 4.11). Cells in Q2-1 and Q4-1 were counted as early and late apoptotic cells, and Q3-
1 were counted as viable cells. The figures briefly showed single treatment of RO-BIR2 
would lead a small group of  KG-1 cells undergoing apoptotic process (Figure 4.11).  
Figure 4.12 summarized the apoptotic cell population upon RO-BIR2 treatment for 48 hours. 
According to cell viability assay, KG-1 cells were resistant to RO-BIR2 monotherapy, which 
was consistent with the apoptosis assay result, that there was a very limited population of 
apoptotic cell on drug treated samples. Under RO-BIR2’s treatment with a high concentration 
of 5000 nM, there was only 13.2% apoptotic cell population was detected (Figure 4.12). 
On U-937 cells, which were dose-dependently responded to RO-BIR2 monotherapy, the 
apoptosis assay indicated RO-BIR2 performed a bit more promising. With the increasing 
dose of RO-BIR2, the viability of U-937 cells decreased accordingly (Figure 4.12). And At 
the concentration of 2500 nM RO-BIR2 treatment, the specific apoptotic population has 
reached more than 15% (Figure 4.12). However, monotherapy of RO-BIR2 still regarded as 
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Figure 4.11. Apoptosis assay of FACS on RO-BIR2 treated KG-1 cells 
 
Apoptosis assay of FACS on DMSO control, 625 nM, 1250 nM, 2500 nM, 5000 nM RO-BIR2 
treated KG-1 cells. Since this KG-1 cell line was obtained from a principle investigator named YQ, 
so I labeled it KG-1 (YQ). Q2-1 and Q4-1 population represents cells undergoing apoptosis, and Q3-






Figure 4.12 apoptotic cell populations of KG-1 and U-937 cells upon RO-BIR2 treatment (48hr) 
KG-1, resistant AML cells;  
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Figure 4.13 Caspase 3/7 activity on AML cell lines and patient samples upon RO-BIR2 
monotherapy 
A. U-937   B. OCI-AML3 C. SE211.   U-937 (cell line) and SE211 (patient sample) had dose-
dependent response to RO-BIR2 according to cell proliferation assay, and OCI-AML3 was very 
resistant toRO-BIR2. In each bar graph, one way ANOVA was used as statistical analysis and all the 
data in the bar represented ± SEM; p-value ≤ 0.001. 
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4.3.3 Caspase 3/7 assay 
Caspase 3/7 is an executioner caspase for the apoptosis intrinsic pathway that directly drives 
the apoptosis pathway, and it can be inhibited by the XIAP linker-BIR2 domain [85]. With 
the 24 hours’ treatment of RO-BIR2, there would be a different activity in the activated 
caspase 3/7, respectively. 
Consistent with cell viability assay results, that U-937 and SE211 were less resistant to RO-
BIR2’s treatment and had a dose-dependent response, a moderate increase of caspase 3/7 
activity was found on drug treated samples (Figure 4.13 A, C). OCI-AML3, which was very 
resistant to RO-BIR2 (at as high as 10 μM’s drug treatment, the inhibition effect still less 
than 5%), the caspase 3/7 activity assay also resulted in very slight change (Figure 4.13 B). 
4.3.4  Western blot analysis 
Western blot was used to investigate the apoptotic related protein expression level change 
after drug treatment. U-937 Cells and KG-1 cells were chosen because of their different 
responses to RO-BIR2. U-937 was less resistant to RO-BIR2 and responded dose-
dependently, while KG-1 and other AML cell lines were even more resistant to the drug 
according to cell proliferation assay. With 48 hours’ RO-BIR2 drug treatment, both U-937 
and KG-1 cells were not observed significant XIAP expression level change, however on 
other apoptotic proteins, these two cell lines behaved differently. 
On U-937 cells, XIAP and caspase 3 level showed no obvious changes upon drug treatment, 
and PARP decreased a bit however cleaved PARP was very weak (Figure 4.14 A). On KG-1 
cells, XIAP, caspase 3, cleaved caspase 3 and Bcl-2 expression level were similar among 
different dose RO-BIR2 treated samples as well, and PARP was not found cleavage at all 
(Figure 4.14 B). 
These results revealed that monotherapy of RO-BIR2 could not induce significant apoptotic 
related proteins’ expression level changes, which was consistent with cell viability assay and 
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Figure 4.14 Western blot analyses of AML cells after RO-BIR2 monotherapy 
A. From left to right, samples in wells were U-937 DMSO control, RO-BIR2 0. 625 μM, RO-BIR2 
1.25 μM, RO-BIR2 2.5 μM, RO-BIR2 5 μM, RO-BIR2 10 μM (48hr); B. From left to right, samples 
in each well were KG-1 DMSO control, RO-BIR2 0. 625 μM, RO-BIR2 1.25 μM, RO-BIR2 2.5 μM, 




4.4 Combination therapy of the BIR2 inhibitor drug RO-BIR2 with TRAIL on AML 
cells and patient samples 
Positive control SW-620 cells were resistant to RO-BIR2, however, combination with drug 
TRAIL displayed very high synergistic effect (CI<1). The result of RO-BIR2 monotherapy 
on both AML cell lines and patient samples were not promising, and we designed 
combination therapy experiment to investigate possible synergism with drug TRAIL and Ara-
C. Hopefully combination therapy also had promising synergy on AML cell lines and patient 
samples. 
TNF related apoptosis-inducing ligand (TRAIL/Apo2L) had been identified to induce 
apoptosis in cancer cells, and it had been reported combination with various 
chemotherapeutic drugs and target drugs would sensitive cancer cells to TRAIL-mediated 
apoptosis [86]. RO-BIR2 was designed to block the activity of XIAP and induce apoptosis, 
and we hypothesize triggering apoptosis through TRAIL, cells would be more sucesptible to 









4.4.1 Cell viability assay  
4.4.1.1 Cell viability assay on AML cells 
With the combination with drug TRAIL, RO-BIR2 had very promising inhibition of cell 
proliferation effect on U-937 cells (less resistant) and HL-60 cells (very resistant) (Figure 
4.16, Figure 4.17).  
TRAIL or RO-BIR2 monotherapy had dose-dependent inhibition effect on U-937 cells, and 
when TRAIL combined with 0.5 μM, 1 μM, 2 μM and 4 μM RO-BIR2, the cell viability 
decrease very rapidly compared to single treatment (Figure 4.16 A). Two-way ANOVA 
analysis showed combination treated samples were significantly different from single drug 
treated samples (Figure 4.16 A). 
The CI value calculated by CompuSyn showed high synergistic effect of TRAIL and RO-
BIR2, with Fa from 0.37 to 0.86, and all the CI value fell below 0.55 (Figure 4.16 B). These 
results revealed that the combination of RO-BIR2 with TRAIL was quite promising for U-
937 cells. 
For RO-BIR2 resistant AML cells, such as HL-60 cells, the combination also led to very 
good result. As it was shown in the figure 4.17A, RO-BIR2 2 μM and 4 μM treatment  had 
little effect on HL-60 cells viability, which responded to TRAIL dose dependently. However, 
with the combination of TRAIL, the cell viability dropped rapidly. Two-way ANOVA 
analysis was performed to confirm the significant difference between combination treated 
and single treated samples as well (Figure 4.17 A), and the CI value suggested the high 
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Figure 4.16 Cell viability assay and CI value of BIR2-TRAIL combination treatment on U-937 
cells 
A. Cell viability assay on U-937 cells. In each bar graph, two way ANOVA was used as statistical 
analysis and all the data in the bar represented ± SEM; p-value ≤ 0.001. B. CI value was calculated by 
CompuSyn software. CI<1 represents synergistic effect. 
  
CI For experimental values (U-937, RO-BIR2-TRAIL) 
TRAIL  BIR2                Fa      CI 
(ng/ml) (nM) 
0.99 500      0.37185            0.213 
2.96 1000      0.776934          0.166 
8.89 2000      0.857726          0.257 
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Figure 4.17 Cell viability assay and CI value of BIR2-TRAIL combination treatment on HL-60 
cells 
A. Cell viability assay on HL-60 cells. In each bar graph, two way ANOVA was used as statistical 
analysis and all the data in the bar represented ± SEM; p-value ≤ 0.001. 
B. CI value was calculated by CompuSyn software. CI<1 represents synergistic effect. 
CI For experimental values (HL-60, RO-BIR2-TRAIL) 
TRAIL  BIR2       Fa          CI 
(ng/ml)              (nM) 
8.89              2000      0.386932    0.366 
8.89              4000      0.405686    0.344 
26.67              2000      0.738653    0.338 
26.67              4000      0.760746    0.309 
80              2000      0.861513    0.547 
80              4000      0.875617    0.496 
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4.4.1.2 Cell viability assay on AML patient samples 
RO-BIR2 and TRAIL combination therapy resulted in a promising inhibition of cell 
proliferation on AML cell lines. On AML patient samples, the synergistic effect was 
observed as well (Figure 4.18). 
One of the AML patient samples, AD330, was chose to do the combination experiment, 
which has dose dependent response to both drugs, RO-BIR2 and TRAIL. Accordingly, we 
calculated IC50 of these two drugs, and used constant ratio combination of them, that 
0.25*IC50 TRAIL+ 0.25*IC50 RO-BIR2, 0. 5*IC50 TRAIL + 0. 5*IC50 RO-BIR2, IC50 
TRAIL+ IC50 RO-BIR2, 2*IC50 TRAIL+ 2*IC50 RO-BIR2, and 4*IC50 TRAIL+ 4*IC50 
RO-BIR2.  
The cell viability assay displayed RO-BIR2 and TRAIL combination treated samples had 
much lower cell viability percentage compared to single drug treated samples, and there was 
a significant difference between them (analyzed by two-way ANOVA) (Figure 4.18 A). The 
CI value also confirmed the high synergism of this combination therapy on patient sample 
AD330 (CI<1) (Figure 4.18 B). 
Consistent with the positive control cell line SW-620, cell viability assay indicated that 
TRAIL and RO-BIR2 combination therapy was quite potent on AML cell lines and patient 
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Figure 4.18 Cell proliferation assay and CI value of BIR2-TRAIL combination treatment on 
patient sample AD330 cells 
 
A. This combination treatment was in constant ratio. The concentrations of drugs were based on IC50 
of drugs calculated by CompuSyn software. Light grey bars represent TRAIL treated cells, dark grey 
bars represent TRAIL combination with RO-BIR2 treated cells, and black bars represent TRAIL 
combination with RO-BIR2 treated cells. Control for TRAIL is PBS, for RO-BIR2 is DMSO, for 
combination treatment is PBS+DMSO mixture. In each bar graph, two way ANOVA was used as 
statistical analysis and all the data in the bar represented ± SEM; p-value ≤ 0.001. 
B. CI value was calculated by CompuSyn software. CI<1 represents synergistic effect. 
 
  
CI For experimental values (AD330, BIR2-TRAIL) 
TRAIL  BIR2      Fa    CI 
(ng/ml)             (nM) 
20             10000       0.608    0.716 
10             5000       0.506    0.546 
5             2500       0.407    0.411 
2.5                    1250            0.197    0.588 
1.25             625       0.163    0.373 
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4.4.2 Apoptosis assay by FACS 
4.4.2.1 Apoptosis assay on AML cell lines 
As cell viability assay displayed, though RO-BIR2 monotherapy varied in response on OCI-
AML3 (very resistant) and U-937 (less resistant), combination therapy with TRAIL resulted 
in a very high synergistic effect on both cell lines. Consistent with that, apoptosis assay 
analysis indicated an increasing percentage of induced apoptotic cell populations on combine 
treated U-937 and OCI-AML3 cells. 
The following FACS figures displayed apoptotic OCI-AML3 cell population upon RO-BIR2 
and TRIAL combination treatment (Q2, Q4) (Figure 4.19). The plots showed TRAIL single 
treatment could induce apoptotic cell population increase, while RO-BIR2 treatment had 
limited effect. Under combination therapy of TRAIL and RO-BIR2, a large increase of OCI-
AML3 cell population was found undergoing apoptosis (Figure 4.19, Figure 4.20 B). 
For U-937 cells, apoptosis assay indicated a potent effect of increasing apoptotic cell 
population on combined treated samples compared to single treated samples. Different from 
OCI-AML3 cells, U-937 cells were more sensitive to this drug combination. With a constant 
ratio combination of a relatively low dose of RO-BIR2 500nM and TRAIL 12.5ng/ml, the 
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Figure 4.19 Apoptosis assay on OCI-AML3 cells upon RO-BIR2 and TRAIL combination 
treatment (72hr) 
OCI-AML3 cells were treated with 2 μM RO-BIR2, 2.96-80.00 ng/ml TRAIL, and combination 
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Figure 4.20 Apoptotic cell population of AML cell lines upon combination therapy of RO-BIR2 
and TRAIL (72hr) 
A. U-937; B. OCI-AML3. U-937 had dose-dependent response to RO-BIR2 according to cell viability 




























































































































4.4.2.2 Apoptosis assay on AML patient samples 
RO-BIR2 and TRAIL combination therapy also had good performance on AML patient 
samples. Cell viability assay indicated combination therapy had potent inhibition effect, and 
apoptosis assay of FACS results were consistent with that. 
Because all the AML patient samples tested had dose dependent responses to RO-BIR2 or 
TRAIL single treatment according to cell viability assay, constant ratio combination therapy 
was designed for patient sample SE211 cells. The apoptosis assay analysis showed that RO-
BIR2 monotherapy could induce cell apoptosis at a relatively high dose (5000 nM, above 20% 
apoptotic cell population), but TRAIL single treatment was not as effective (Figure 4.21). 
Combination treatment had much better performance, even at a very low dose of drug 
combination (RO-BIR2 1250 nM + TRAIL 6.25 ng/ml), the apoptotic population could be 
increased to more than 40%, while the population of RO-BIR2 or TRAIL single treatment 












Figure 4.21 Apoptosis assay on patient sample SE-211 (48hr) 




































































4.4.3 Caspase 3/7 assay 
As introduced in the former part, caspase 3/7 is an executioner caspase for the apoptosis 
intrinsic pathway that directly drives the apoptosis pathway, and it can be inhibited by the 
XIAP linker-BIR2 domain [87]. Cell viability assay and apoptosis assay had indicated that 
RO-BIR2 and TRAIL combination treatment had a potent effect of inhibition of cell growth 
and could induce apoptosis. So under this drug combination treatment, there would be a 
different activity in the activated caspase 3/7 on AML cells, respectively. 
 
4.4.3.1 caspase 3/7 assay on AML cell lines  
Combination therapy of RO-BIR2 with TRAIL on OCI-AML3 and U-937 cells resulted in 
increased activity of caspase 3/7, and two-way ANOVA indicated its significance (Figure 
4.22 A, B). Another conclusion of this graph was OCI-AML3 benefited more from the 
combination therapy, with a much higher increased caspase activity (around 300%) under 
low doses of TRAIL treatment (0.99 ng/ml and 2.96 ng/ml, and TRAIL single treated 
samples only had the caspase 3/7 activity of 100-130%) (Figure 4.22 B). On U-937 cells, 
though combination treatment could increase caspase 3/7 activity, the increase percentage 
was not as potent as on OCI-AML3 cells. Interestingly, for RO-BIR2 or TRAIL single 
treatment, U-937 cells were more sensitive compared to OCI-AML3 cells, which had a 
higher induced caspase 3/7 activity (Figure 4.22 A).  
This result may suggest RO-BIR2 could benefit AML patients, and combination with low 
dose of TRAIL was considerable to provide a better therapy. 
 
4.4.3.2 caspase 3/7 assay on AML patient samples 
Patient samples study were important for the drug development. The same as cell viability 
assay, caspase 3/7 assay on AML patient samples also used constant ratio combination.  
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The assay indicated that TRAIL monotherapy had very limited affection of caspase 3/7 
activity on patient sample SE211 cells, and the caspase activity remained around 100% at the 
presence of all doses of TRAIL tested from low to high concentrations (Figure 4.20). On the 
other hand, caspase 3/7 activity increased with RO-BIR2’s concentration, which was 
consistent with the cell viability result. Moreover, once RO-BIR2 combined with TRAIL, the 
caspase 3/7 activity increased apparently, and the significance of combination therapy was 
confirmed by two-way ANOVA (Figure 4.20).  
This result suggested the possible application of RO-BIR2 monotherapy and combination 
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Figure 4.22 Caspase 3/7 activity on AML cell lines upon TRAIL and RO-BIR2 combination 
therapy 
A. U-937; B. OCI-AML3. U-937 had dose-dependent response to RO-BIR2 according to cell viability 
assay, and OCI-AML3 was very resistant to RO-BIR2. In each bar graph, two way ANOVA was used 









































Figure 4.23 Caspase 3/7 activity on patient sample SE211 upon TRAIL and RO-BIR2 
combination therapy 
SE211 had dose-dependent response to RO-BIR2 according to cell viability assay. The concentrations 
of drugs were based on the IC50 calculated by CompuSyn software. In each bar graph, two way 







































































































4.4.4  Western blot analysis 
As shown in the former part, RO-BIR2 monotherapy couldn’t lead to the expression level 
change of apoptotic related proteins, such as XIAP, caspase 3, PARP, Bcl-2, etc. However, 
combination therapy displayed a number of apoptotic proteins changed over treated samples. 
It had been confirmed by cell viability assay that combination treatment of RO-BIR2 and 
TRAIL had a very high synergistic effect on OCI-AML3 cells, and apoptosis assay and 
caspase assay also indicated an increasing population of apoptotic cells with higher caspase 
3/7 activity on treated samples. Besides, OCI-AML3 cells responded better to low doses of 
drug combination therapy than U-937 cells. 
Consistent with these results, with 48 hours’ RO-BIR2 and TRAIL treatment on OCI-AML3 
cells, western blot analysis indicated that combined treated samples had decreased XIAP 
expression level, cleavage of caspase 3, slight cleavage of caspase 7, and cleaved PARP. 
Other proteins like Bcl-2, caspase 8 and caspase 9 didn’t present significant changes (Figure 
4.24).  
 
In conclusion, similar to the positive control cell line SW620, RO-BIR2 and TRAIL 
combination led to promising effect on both AML cell lines and AML patient samples. RO-
BIR2 and TRAIL combination possibly functioned by inhibiting XIAP, inducing the activity 
of caspase 3 and caspase 7 activities and downstream PARP cleavage, and processed to cell 
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Figure 4.24 Western blot analysis of OCI-AML3 after TRAIL and RO-BIR2 combination 
therapy 
From left to right, samples in wells were PBS control (for TRAIL), DMSO control (for RO-BIR2), 
mixture control (for combination), RO-BIR2 2 μM, TRAIL 20 ng/ml, TRAIL 10ng/ml, RO-BIR2 








BIR-2    TRAIL  Combi   BIR-2   TRAIL     TRAIL    BIR-2+TRAIL  BIR-2+TRAIL  
  ctrl        ctrl        ctrl      2uM      20ng/ml    10ng/ml    20ng/ml            10ng/ml 
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4.5 Combination therapy of RO-BIR2 with Ara-C on AML cells and patient samples 
It had been confirmed that despite of the resistant responses of AML cells and patient sample 
to RO-BIR2, combination therapy with TRAIL had a very potent inhibition effect on cell 
viability, inducing cells undergo apoptosis process, increasing activity of caspase 3/7, and 
leading to a series of apoptotic related protein expression levels changes, such as cleavage of 
caspase 3/7, decrease of XIAP, increase of Bax, etc. These results suggested the potential 
application of combination therapy of RO-BIR2 and TRAIL on clinical trial. The 
combination required very low doses to reach expected inhibition of cell growth, thus 
reducing harm to healthy cells and avoid severe side effects. 
Ara-C had been a very commonly used chemotherapeutic drug to treat AML and non-
Hodgkin lymphoma [88, 89].Unlike targeted drug exploit molecular dependencies in tumor, 
chemotherapeutic drugs works by interfering with DNA synthesis [90]. 
Combination therapy of RO-BIR2 targeting XIAP BIR2 domain with current widely used 
chemo-drug Ara-C was aimed to investigate the possible synergism and the further probable 
application for AML patient treatment in clinic. 
4.5.1 Cell viability assay  
4.5.1.1 Cell proliferation assay on AML cells 
With the combination of chemotherapeutic drug Ara-C, RO-BIR2 had very promising 
inhibition effect of cell viability on both U-937 cells (less resistant to RO-BIR2) and KG-1 
cells (very resistant to RO-BIR2) (Figure 4.24 A, B). 
Ara-C had dose-dependent inhibition effect on U-937 and KG-1 cells, and when it combined 
with 2 μM or 4 μM RO-BIR2, the cell viability decrease very rapidly compared to single drug 
treatment. Besides, combination therapy of higher dose of 4 μM RO-BIR2 performed better 
than lower dose of 2 μM RO-BIR2. Two-way ANOVA analysis was used and indicated 
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combination treated samples were significantly different from single treated samples on both 
U-937 and KG-1 cells. (Figure 4.25 A, B) 
The CI value calculated by CompuSyn software stated that for U-937 cells, combination of 
RO-BIR2 with Ara-C led to relatively high synergistic effect (CI<1) except at very high dose 
of Ara-C (1800nM). Because at that high dose of Ara-C (1800nM), Ara-C monotherapy 
could led to death of most cells (cell viability below 20%), but with the addition of RO-BIR2, 
cell viability was still found decreased. (Table 4.2) 
Combination therapy on KG-1 cells led to great decrease of cell viability compared to RO-
BIR2 or Ara-C monotherpay as well. Due to KG-1 cells were not as sensitive to Ara-C drug 
as U-937 cells, with 22.22 nM to 600 nM Ara-C treatment, cell viability slightly increased, 
thus the CI value couldn’t be calculated (CompuSyn software requires inhibition value > 0, 
inhibition value <0 could not be entered into the software). However we could still drew the 
conclusion that combination of RO-BIR2 and Ara-C also worked effectively on KG-1 cells, 
that even combined with very low doses of Ara-C, cell viability decreased greatly (Figure 
4.25 B). 
4.5.1.2 Cell viability assay on AML patient samples 
Combination treatment of RO-BIR2 and Ara-C also works for AML patient samples. Two of 
the AML patient samples obtained from NUH, AD330 and AD448 were chosen to be tested 
for the combination therapy.  
All the AML patient samples had dose-dependent responses to RO-BIR2 based on cell 
viability assay, and these samples also responded to Ara-C dose dependently, so constant 
ratio combination therapy depending on IC50 of RO-BIR2 and Ara-C could be performed. 
On both AD330 and AD448 cells, RO-BIR2 in addition with Ara-C had great inhibition 
effect on cell viability (Figure 4.26 A, B).  AD448 cells had better response to this 
combination, that even at low doses of combination (RO-BIR2 1.25 μM + Ara-C 175nM), the 
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inhibition effect was as high as 0.53 (Figure 4.26 B). It was of great significance of 
combination treatment at low doses to reach potent effect, thus reducing drug toxicity and 
side effects of chemotherapy on AML patients. On AD330 cells, the combination also 
showed good synergism (CI<1). Two-way ANOVA was used to as statistical analysis and 
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Figure 4.25 Cell viability assay on AML cell lines upon RO-BIR2 and Ara-C combination 
therapy 
A. RO-BIR2 and Ara-C combination therapy on U-937 cells; B. RO-BIR2 and Ara-C combination 
therapy on OCI-AML3 cells. In each bar graph, two way ANOVA was used as statistical analysis and 
all the data in the bar represented ± SEM; p-value ≤ 0.001.  
 
 
Dose RO-BIR2 (μM) Dose Ara-C (nM) Effect CI 
2.0 1800.0 0.9 1.09764 
2.0 600.0 0.87 0.45962 
2.0 200.0 0.69 0.35757 
2.0 66.67 0.42 0.28295 
4.0 1800.0 0.9 1.09764 
4.0 600.0 0.88 0.42837 
4.0 200.0 0.76 0.27257 
4.0 66.67 0.53 0.20119 
 
Table 4.2   CI value of RO-BIR2 and Ara-C combination therapy on U-937 cells 
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Figure 4.26 Cell viability assay on AML patient samples upon RO-BIR2 and Ara-C 
combination therapy 
A. Cell viability assay of RO-BIR2 and Ara-C combination therapy on AD330 cells; B. Cell 
proliferation assay of RO-BIR2 and Ara-C combination therapy on AD448 cells. The combination of 
the two drugs used constant ratio. In each bar graph, two way ANOVA was used as statistical analysis 
and all the data in the bar represented ± SEM; p-value ≤ 0.001.  
 




(nM) Effect CI 
20 2800 0.97 0.20418 
10 1400 0.94 0.21631 
5 700 0.88 0.23914 
2.5 350 0.76 0.34528 
1.25 175 0.53 0.44894 
                     
                           A. AD448                                                 B. AD330 
 
Table 4.3   CI value of RO-BIR2 and Ara-C combination therapy on AML patient samples 
 
A. CI value table of RO-BIR2 and Ara-C combination treatment on patient sample AD448; B. CI 
value table of RO-BIR2 and Ara-C combination treatment on patient sample AD330. CI<1, 




(nM) Effect CI 
20 2800 0.779 0.29769 
10 1400 0.702 0.29117 
5 700 0.573 0.37161 
2.5 350 0.421 0.51557 
1.25 175 0.313 0.56162 
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4.5.2  Apoptosis assay by FACS 
4.5.2.1 Apoptosis assay on AML cel llines 
The following FACS figures displayed apoptotic cell population of RO-BIR2 and Ara-C 
combined treated U-937 cells (Figure 4.27). The figures briefly showed RO-BIR2 or Ara-C 
monotherapy led to moderate apoptotic cell population increase, and combination therapy 
could induce more cells stepping into apoptosis process (Figure 4.27). Population on plots 
Q2-1 and Q4-1were calculated as early and late apoptotic cells, and Q3-1 population were 
calculated as viable cells (Figure 4.27). 
The following figure 4.28 calculated U937, KG-1 and OCI-AML2 cell populations 
undergoing apoptotic process after RO-BIR2 and Ara-C combination treatment for 48 hours. 
Compared to single treatment, these two drugs’ combination had some additional effect to 
increase apoptotic cell pupation (Figure 4.28 A, B).  
However, it seemed the combination of RO-BIR2 with chemotherapeutic Ara-C was not as 
potent as combined with drug TRAIL. Very low doses of RO-BIR2 and TRAIL combination 
could achieve promising synergistic result, but RO-BIR2 and Ara-C combination required 
higher concentrations.  
4.5.2.2 Apoptosis assay on AML patient samples 
The combination of RO-BIR2 and Ara-C also worked well on AML patient samples. Though 
not as potent as RO-BIR2 and TRAIL combination, cell viability assay of Ara-C combination 
showed synergistic effect, and apoptosis assay of FACS result was consistent with that. 
Two AML patient samples, SE211 and AD307 were chosen to do the apoptosis assay upon 
48 hours’ combination therapy. The results displayed similar outcomes as combination 
therapy on AML cells. Monotherapy of RO-BIR2 or Ara-C could induce cells undergo 
apoptosis, but the combination of RO-BIR2 with Ara-C would further increase the apoptotic 
cell population (Figure 4.29). 
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However, for AML patients, it is of great significance to reduce drug dose but achieve the 
expected treatment outcome and avoid side effects and lower drug toxicity. Targeting this 
goal, drug TRAIL had better performance compared to Ara-C, and the former was worthy of 






Figure 4.27 Apoptosis assay of FACS on U-937 cells upon RO-BIR2 and Ara-C treatment 
According to FACS result, Q2-1 and Q4-1 population were counted as apoptotic cells, and Q3-1 















































































































Figure 4.28 Apoptosis assay on AML cell lines upon RO-BIR2 and Ara-C combination 
treatment 
A. Apoptosis assay on U-937 cells (48hr); B. Apoptosis assay on KG-1 cells (48hr). C. Apoptosis 
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Figure 4.29 Apoptosis assay on AML patient samples upon RO-BIR2 and Ara-C combination 
treatment 
A. Apoptosis assay on patient sample SE211 cells (48hr); B. Apoptosis assay on patient sample 




4.5.3 Caspase 3/7 assay 
Apoptosis assay by FACS indicated combination therapy of RO-BIR2 and Ara-C could 
induce cells undergoing apoptosis process, and this process was accompanied with activation 
of caspase 3/7, which was confirmed by caspase activity assay (Figure 4.30).   
On U-937 cells, 2 μM RO-BIR2 monotherapy had limited effect on caspase activation, 
however, combined with a low dose of Ara-C (22.22 nM), the caspase activity increased 
rapidly, from 100% to more than 200% (Figure 4.30 A). With increasing dose of Ara-C , U-
937 cells had a higher caspase activity (Ara-C 1800 nM + RO-BIR2 2 μM, caspase activity 
increased to more than 300%) (Figure 4.30 A).  
On patient sample SE211, which responded to RO-BIR2 and Ara-C dose-dependently, 
combination therapy at constant ratio based on the two drugs’ IC50 was performed. The 
caspase 3/7 activity increased with higher dose of RO-BIR2 and Ara-C, and combination 
treatment showed there was some synergistic effect than single drug treatment but not as 
potent as on U-937 cells (Figure 4.30 B). Two-way ANOVA indicated the significant 
difference between combined and single drug treated samples (Figure 4.30 A, B). All these 
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Figure 4.30 Caspase assay on AML cells and patient sample upon RO-BIR2 and Ara-C 
combination therapy 
A. caspase 3/7 activity assay on U-937 cells (24hr), the combination of RO-BIR2 and Ara-C used 
non-constant ratio; B. caspase 3/7 activity assay on patient sample SE211 cells, the combination of 
RO-BIR2 and Ara-C used constant ratio. In each bar graph, two way ANOVA was used as statistical 





4.5.4  Western blot analysis 
As shown in the RO-BIR2 monotherapy section (section 4.2), monotherapy of RO-BIR2 
couldn’t induce significant expression level changes of XIAP, caspase 3, PARP, Bcl-2 
proteins, etc. But when RO-BIR2 combined with TRAIL, a number of apoptotic proteins 
changed within treated samples, such as cleavage of caspase 3, slight cleavage of caspase 7, 
cleaved PARP and XIAP decrease. 
Combined RO-BIR2 with chemo-drug Ara-C, similar result was found on AML cells and 
patient samples, as indicated in the following parts. 
4.5.4.1 Western blot analysis on AML cells lines 
It had been confirmed that U-937 cells responded to RO-BIR2 dose-dependently with a 
relatively high IC50, and combination therapy with chemotherapeutic drug Ara-C showed 
great synergism, along with activation of caspase 3/7 and increase of cell population 
undergoing apoptosis.  
Western blot results of U-937 cells were consistent with former assays. Combination of 1 μM 
RO-BIR2 and 75 nM Ara-C, Bad, cleavage of caspase 3, caspase 8 and caspase 7 were found 
on combined treated U-937 cells (Figure 4.31).   
On KG-1 cells, however, there were no significant differences of XIAP, cleavage caspase 3, 
cleavage caspase 7, Bcl-2, Bax and Bad levels among combined and single treated samples 
(Figure 4.33).  Interestingly, cleavage of caspase 8 was even higher in Ara-C single treated 
samples, and caspase 9 cleavage was not observed, either (Figure 4.33).  As showed in the 
former part, KG-1 cells with combination therapy could induce potent apoptotic cell 
population increase, thus it is interesting to do some further analysis of KG-1 cells’ resistance 
to RO-BIR2 and Ara-C combination therapy. 
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4.5.4.2 Western blot analysis on AML patient samples 
On AML patient sample SE-211 cells, similar result could be observed after combination 
therapy of RO-BIR2 and Ara-C.  Cleavage of caspase 3 and cleaved PARP could be observed 
on combined treated samples, and the cleavage protein levels were significantly higher than 
control and single treated samples (Figure 4.32). These results suggested that induction of the 
apoptotic machinery is important for the therapeutic effect of the combination and this 
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Figure 4.32 Western blot analysis on SE-211 cells upon RO-BIR2 and Ara-C combination 
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4.6 Microarray, GEP analysis and IPA analysis 
As stated in the former section, U-937 cells responded differently compared to other AML 
cell lines. U-937 cells had dose-dependent response to RO-BIR2 treatment. However, the 
IC50 was relatively high. Other AML cell lines, including OCI-AML2, OCI-AML3, KG-1, 
HL60 and MV4-11 cells, were quite resistant to RO-BIR2. Even at very high dose of the drug 
treatment, the inhibition of cell viability was below 5%. The different responses of AML cells 
were worthy of further investigation. 
To analyze why U-937 had different response to RO-BIR2, OCI-AML3 cells were used as a 
control cell line to perform microarray. U-937 and OCI-AML3 cells were treated with DMSO 
and 2 μM RO-BIR2 (duplicates), and the RNA extracted were used to do Human Gene 1.0ST 
array for gene expression profiling. GCOS and GeneSpring were used to analysis the 
microarray data and a two-fold filter was applied. Compared the differentially expressed 
genes in RO-BIR2 treated OCI-AML3 cells following RO-BIR2 treatment, 27 unique up-
regulated genes (Appendix 1) and 487 down-regulated genes were found in U-937 cells 
(Appendix 2). (Figure 4.34) 
 




As many as 27 unique up-regulated genes and 487 unique down-regulated genes were found 
in U-937 compared to OCI-AML3 following treatment. These genes may contribute to the U-
937 cells’ different response to RO-BIR2. 
The following figures listed the top 10 up-regulated genes and top 20 down-regulated genes. 
Up-regulated genes included GSTM2, CRYAB, RNU6ATAC, SNORD14E, RGS2, 
TSPAN12, ERRFI1, ARRDC4, PGLYRP4 and FN1 (Figure 4.35 A). Down-regulated genes 
included PLEK, IFI44, CTSG, ITGA4|CERKL, RNASE2, IFIT1, ATP8B4, CXL10, FAP, 
SAMD9, MX2, C5orf13, SLFN5, IFI44L, AOAH, ECRP, RNASE3, CRYLTR1, TRIM22 
and SAMD9L (Figure 4.35 B).  
A number of these unique up-regulated and down-regulated genes were validated by qRT-
PCR. It was very clear that RO-BIR2 treated U-937 cells had much higher expression of up-
regulated genes, and much lower expression of down-regulated genes compared to U-937 
control sample and OCI-AML3 cells (Figure 4.36).  
The unique down-regulated genes in U-937 cells were further analyzed by Gene Ontology 
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Figure 4.35 Top unique regulated genes in U-937 cells 
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Figure 4.36 Validation of top regulated genes on U-937 cells and OCI-AML3 cells 
  


























































































4.6.2 GEP analysis 
The down-regulated geneset was imported to GO for analysis, and function annotation, gene 
function classification and KEGG pathway were obtained.  
The result was listed in the table 4.4, which grossly suggest the down-regulation of genes 
involved in various processes of immune response. Green items suggest down regulation of 
genes involved in inflammatory response, including inflammatory response, plasma 
extracellular, signal peptide in membrane, leukocyte chemotaxis, T cell activation, etc. Blue 
items suggest down regulation of Fc receptors, including SH3 domain, Fc receptor, guanine 
nucleotide exchange factor, etc, which could inhibit various immune cells. Orange items 
suggest down regulation of MHC class 1 genes, including MHC class 1, cell adhesion, 
immunoglobulin, etc. And Pathway items from KEGG, Biocarta or BIND are underlined in 
member id column and those that show significant enrichment are marked in bold, which wre 
cell adhension molecules (CAMs), antigen processing and presentation, Fc gamma R-




No Name* Member ID Score 
1 Inflammatory response Defense response (GOBP 1), response to wounding (GOBP), inflammatory response 
(GOBP) 
13.950 
2 Plasma extracellular 
membrane 
Plasma membrane part (GOCC 2), integral to plasma membrane (GOCC), intrinsic to 
plasma membrane (GOCC), topological domain: extracellular (UP 3) 
5.67 
3 Signal peptide in 
membrane 
Disulfide bond (UP), plasma membrane (GOCC), disulfide bond (SP 4), signal (SP), 
signal peptide (UP), membrane (SP), glycosylation site:N-linked (GlcNAc…) (UP), 
topological domain: extracellular (UP), glycoprotein (SP), topological domain: 
cytoplasmic (UP), transmembrane region (UP), transmembrane (SP), intrinsic to 
membrane (GOCC), integral to membrane (GOCC) 
4.95 
4 Leukocyte chemotaxis Taxis (GOBP), chemotaxis (GOBP), leukocyte migration (GOBP), leukocyte 
chemotaxis (GOBP), cell chemotaxis (GOBP), locomotory behavior (GOBP), 
behavior (GOBP), cell motion (GOBP), cell migration (GOBP), localization of cell 
(GOBP), cell motility (GOBP), neutrophil chemotaxis (GOBP) 
4.87 
5 SH3 domain Sh3 domain (SP), Src homology-3 domain (Interpro), SH3 (Smart), SH3 (UP) 4.22 
6 MHC class 1 Heterodimer (SP), class I histocompatibility antigen (PIR 5), antigen processing and 
presentation (GOBP), region of interest: alpha-3 (UP), mhc I (SP), antigen processing 
and presentation of peptide antigen (GOBP), cell adhesion molecules (CAMs) 
(KEGG 6), region of interest: alpha-2 (UP), region of interest: alpha-1 (UP), MHC 
class I, alpha chain, alpha1 and alpha2 (Interpro), immunoglobulin C1-set (Interpro), 
MHC protein complex (GOCC), MHC class I-like antigen recognition (Interpro), 
MHC class I protein complex (GOCC), domain:Ig-like C1-type (UP), antigen 
processing and presentation of peptide antigen via MHC class I (GOBP), MHC class 
I receptor activity (GOMF 7), IGc1 (Smart), antigen processing and presentation 
(KEGG), immunoglobulin/major histocompatibility complex, conserved site 
(Interpro), region of interest: connecting peptide (UP), graft-versus-host disease 
(KEGG), allograft rejection (KEGG), transplantation antigen (SP), viral myocarditis 
(KEGG), MHC class I, alpha chain, C-terminal (Interpro), type I diabetes mellitus 
(KEGG), autoimmune thyroid disease (KEGG), 
signal_peptides_(MHC)_class_I_molecules (BBID 8), beta-2-microglobulin (BIND 
9), mhc ii (SP), endocytosis (KEGG) 
4.03 
7 T cell activation Leukocyte activation (GOBP), cell activation (GOBP), lymphocyte activation 
(GOBP), T cell activation (GOBP), T cell selection (GOBP), leukocyte 
differentiation (GOBP), hemopoiesis (GOBP), hemopoietic or lymphoid organ 
development (GOBP), immune system development (GOBP), lymphocyte 




Phagocytosis (GOBP), membrane invagination (GOBP), endocytosis (GOBP), 
membrane organization (GOBP), visicle-mediated transport (GOBP) 
3.54 
9 Cell adhesion Cell adhesion (GOBP), biological adhesion (GOBP), cell adhesion (GP) 3.32 
10 Immunoglobulin Immunoglobulin-like fold (Interpro), immunoglobulin-like (Interpro), 
immunoglobulin subtype (Interpro), immunoglobulin domain (SP), domain:Ig-like 
C2-type 1 (UP), domain:Ig-like C2-type 2 (UP), IG (Smart), immunoglobulin 
(Interpro), Ig-like C2-type 3 (UP), immunoglobulin V-set (Interpro) 
3.30 
11 Fc receptor Fc gamma R-mediated phagocytosis (KEGG), B cell receptor signaling pathway 
(KEGG), Fc epsilon RI signaling pathway (KEGG), T cell receptor signaling 
pathway (KEGG) 
3.13 
12 Guanine nucleotide 
exchange factor 
Guanine-nucleotide releasing factor (SP), domain:DHR-1 (UP), domain:DHR-2 (UP) 2.99 
13 Heparin binding Carbohydrate binding (GOMF), polysaccharide binding (GOMF), pattern binding 
(GOMF), glycosaminoglycan binding (GOMF), heparin binding (GOMF) 
2.55 
14 SH2 domain SH2 domain(SP), SH2 motif (Interpro), SH2 (Smart), domain:SH2 (UP) 2.45 
15 Pleckstrin homology Domain:PH(UP), pleckstrin homology (Interpro), PH (Smart), Pleckstrin homology-
type (Interpro) 
2.43 
16 Lectin Lectin (SP), sugar binding (GOMF), C-type lectin-like (Interpro), domain:C-type 
lectin(UP), C-type lectin, conserved site (Interpro), C-type lectin (Interpro), CLECT 
(Smart) 
2.42 
17 Humoral immune 
response 
Positive regulation of immune system process (BOGP), immune effector process 
(GOBP), adaptive immune response (GOBP), adaptive immune response based on 
somatic recombination (GOBP), leukocyte mediated immunity (GOBP), lymphocyte 
mediated immunity (GOBP), immunoglobulin mediated immune response (GOBP), 
activation of immune response (GOBP), B cell mediated immunity (GOBP), positive 
regulation of immune response (GOBP), positive regulation of response to timulus 
(GOBP), innate immunity (SP), humoral immune response (GOBP), complement 
pathway (SP), complement activation, classical pathway (GOBP), humoral immune 
response mediated by circulating immunoglobulin (GOBP), complement and 
coagulation cascades (KEGG), complement activation (GOBP), activation of plasma 




response (GOBP), protein processing (GOBP), protein maturation by peptide bond 
cleavage (GOBP), plasma (SP), protein maturation (GOBP) 
18 Lymphocyte activation Positive regulation of immune system process (GOBP), regulation of cell activation 
(GOBP), positive regulation of cell activation (GOBP), regulation of leukocyte 
activation (GOBP), regulation of lymphocyte activation (GOBP), positive regulation 
of T cell activation (GOBP), regulation of T cell activation (GOBP), positive 
regulation of lymphocyte activation (GOBP), T cell selection (GOBP), positive 
regulation of leukocyte activation (GOBP), positive regulation of lymphocyte 
differentiation (GOBP), regulation of lymphocyte proliferation (GOBP), regulation 
of leukocyte proliferation (GOBP), regulation of mononuclear cell proliferation 
(GOBP), regulation of B cell differentiation (GOBP), positive regulation of T cell 
differentiation (GOBP), positive regulation of B cell activation (GOBP), positive 
regulation of cell differentiation (GOBP), regulation of alpha-beta T cell activation 
(GOBP), positive regulation of B cell differentiation (GOBP), positive regulation of 
T cell proliferation (GOBP), regulation of T cell proliferation (GOBP), regulation of 
lymphocyte differentiation (GOBP), positive regulation of alpha-beta T cell 
activation (GOBP), regulation of alpha-beta T cell differentiation (GOBP), regulation 




Actin filament-based process (GOBP), actin cytoskeleton organization (GOBP), actin 
filament organization (GOBP), cytoskeleton organization (GOBP) 
2.13 
20 Lymphocyte adhesion Monocyte and its surface molecules (Biocarta), neutrophil and its surface 
molecules (Biocarta), integrin-mediated signaling pathway (GOBP), leukocyte 
adhesion (GOBP), adhesion molecules on lymphocyte (Biocarta), adhesion and 
diapedesis of lymphocytes (Biocarta), short sequence motif:GFFKR motif (UP), cells 
and molecules involved in local acute inflammatory response (Biocarta), adhesion 
and diapedesis of granulocytes (Biocarta), integrin complex (GOCC), receptor 
complex (GOCC), repeat:FG-GAP 7 (UP), repeat:FG-GAP 1 (UP), repeat:FG-GAP2 
(UP), repeat:FG-GAP3 (UP), repeat:FG-GAP4 (UP), repeat:GF-GAP5 (UP), 
repeat:FG-GAP6 (UP), integrin alpha-2 (Interpro), integrin alpha chain (Interpro), 
integrin alpha chain, C-terminal cytoplasmic region, conserved site (Interpro), 
integrin alpha beta-propellor (Interpro), integrin (SP), int_alpha (Smart), FG-GAP 
(Interpro), regulation of actin cytoskeleton (KEGG), integrin alpha chain, C-terminal, 
cytoplasmic region (Interpro), von Willebrand factor, type A (Interpro), 
domain:VWFA (UP), VWA (Smart), cell-cell adhesion (GOBP) 
2.12 
21 Actin filament Cell leading edge (GOCC), actin cytoskeleton (GOCC), actin filament (GOCC), 
ruffle (GOCC), actin filament binding (GOMF), actin filament organization (GOBP), 
actin filament bundle formation (GOBP) 
2.06 
22 PAAD/DAPIN domain HIN-200/IF120x (Interpro), domain:DAPIN (UP), Pyrin (Interpro) 2.05 
23 Chemokine Chemotaxis (SP), inflammation (SP), inflammatory response (SP), small chemokine, 
interleukin-8-like (Interpro), GProt-coupled_Rec_T_Cell_med_inflamm (BBID), 
Chemokines_in_EAE (BBID), chemokine activity (GOMF), SCY (Smart), 
chemokine receptor binding (GOMF), cytokine (SP), toll-like receptor signaling 
pathway (KEGG), cytokine-cytokine receptor interaction (KEGG), small chemokine, 
C-C group, conserved site (Interpro), small inducible chemokine, C/CC types (PIR), 
regulation of viral genome replication (GOBP), cytokine activity (GOMF), regulation 
of viral reproduction (GOBP), chemokine_families (BBID), cytokine_astrocytes 
(BBID), HIV1gp4 (BIND) 
2.02 
24 Inflammatory response Regulation of response to external stimulus (GOBP), regulation of inflammatory 
response (GOBP), negative regulation of response to stimulus (GOBP), negative 
regulation of defense response (GOBP), negative regulation of response to external 
stimulus (GOBP), negative regulation of inflammatory response (GOBP), positive 
regulation of response to external stimulus (GOBP) 
1.99 
25 Leukocyte activation Regulation of leukocyte activation (GOBP), regulation of lymphocyte activation 
(GOBP), negative regulation of immune system process (GOBP), regulation of 
lymphocyte proliferation (GOBP), regulation of leukocyte proliferation (GOBP), 
regulation of mononuclear cell proliferation (GOBP), negative regulation of 
leukocyte activation (GOBP), negative regulation of cell activation (GOBP), negative 
regulation of lymphocyte activation (GOBP), negative regulation of lymphocyte 
proliferation (GOBP), negative regulation of leukocyte proliferation (GOBP), 
negative regulation of mononuclear cell proliferation (GOBP), negative regulation of 
T cell activation (GOBP) 
1.91 
 





4.6.3 IPA analysis 
The unique up-regulated and down-regulated genes were imported into IPA software for 
analysis, and gene network and biological function were obtained for further experiment. 
The following table 4.6 summarized the top networks of the unique regulated genes on 2 μM 
RO-BIR2 treated U-937 cells, including 1) tissue morphology, cell cycle, gastrointerstinal 
disease; 2) Dermatological diseases and conditions, infectious disease, gastrointestinal 
disease; 3) Infectious disease, neurological disease, psychological disorders; 4) hereditary 
disorder, immunological disease, inflammatory disease; 5) post-translational modification, 
protein degradation, protein synthesis (Table 4.5). The upstream regulators consisted of 
lipopolysaccharide, IFNG, TGM2, tretinoin and IRF7 (Table 4.6), which was worthy of 
further research. 
Canonical pathway analysis displayed pathways involved of the regulated genes. A number 
of top canonical pathways were involved in immune response, such as communication 
between innate and adaptive immune cells, antigen presentation pathway, nature killer 
signaling, etc (Figure 4.38) 
Figure 4.38 and Figure 4.39 displayed the unique regulated genes involved in network 1 and 
network 4. Green color meant down-regulated genes and red color meant up-regulated genes. 
The number beside the gene name represented the fold change of this gene. Solid lines meant 
the direct interactions between genes, while pecked lines meant indirect interactions. (Figure 





ID Associated Network Functions score
1 Tissue Morphology, Cell Cycle, Gastrointestinal Disease 34
2 Dermatological Diseases and Conditions, Infectious Disease, Gastrointestinal Disease  33
3 Infectious Disease, Neurological Disease, Psychological Disorders 32
4 Hereditary Disorder, Immunological Disease, Inflammatory Disease 30
5 Post-Translational Modification, Protein Degradation, Protein Synthesis 28
 




























Figure 4.39 Associated network of function of hereditary disorder, immunological disease, and 
inflammatory disease  
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4.7 XIAP shRNA knock down on AML cells 
To better understand the role of XIAP, six lentiviral XIAP shRNA was used to knock down 
XIAP in AML cells. NEON transfection system was used to transfect shRNA to cells, and 
after transfection, qRT-PCR and western blot were used to check the knock down efficiency. 
4.7.1 qRT-PCR of XIAP on AML cells with XIAP shRNA knock down 
Among the six XIAP shRNAs, 1-D-09, 1-D-10, 1E-01, 1E-02, 1E-03 and 1E-04, two of them 
had the best knock down efficiency (1-D-09, 1-D-10), and these two shRNA were used for 
further experiment like apoptosis assay and western blot. 
XIAP shRNA 1-D-09 and 1-E-01 transfection on two AML cell lines (HL-60 and KG-1) led 
to the decrease of relative XIAP expression by qRT-PCR (Figure 4.40). It was obvious that 
the knock down efficiency on HL-60 cells was better than KG-1 cells. 
The cell viability assay showed there was some decrease of cell viability percentage on HL-
60 and KG-1 cells after XIAP knock down compared to control samples (Figure 4.41). XIAP 
shRNA 1-E-01 had better inhibition effect than shRNA 1-D-09. Besides, Apoptosis assay on 
KG-1 cells after XIAP shRNA knock down resulted in slight increase of apoptotic cell 
population (Figure 4.42). And western blot resulted displayed the XIAP expression decrease 
and cleavage of caspase 3, cleavage of caspase 7, and cleaved PARP increase on HL-60 and 
KG-1 cell with XIAP shRNA knock down (Figure 4.43). 
4.7.2  Cell viability assay on AML cells upon XIAP knock down 
There was another interesting finding that after XIAP knock down, AML cells, for instance, 
HL-60 cells become more sensitive to TRAIL treatment compared to normal HL-60 cells 
(Figure 4.44). It inspired us that with XIAP inhibitor treatment, AML cells probably had 
better outcomes with targeted or chemotherapeutic drugs. 
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All these result suggested knock down of XIAP had mimic function to XIAP inhibitors, thus 
XIAP was an important target to induce apoptosis and kill cancer cells. Drugs targeting XIAP 






























Figure 4.40 XIAP shRNA knock down on AML cell lines 
In each bar graph, two way ANOVA was used as statistical analysis and all the data in the bar 







































Figure 4.41 Cell viability assay on AML cell lines after XIAP shRNA knock down (24hr) 
In each bar graph, two way ANOVA was used as statistical analysis and all the data in the bar 
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Figure 4.43 Western blot analysis of AML cell lines after XIAP shRNA knock down (72hr) 
A. Western blot analysis of HL60 cells, from left to right, the samples in wells were shRNA ctrl, 
XIAP shRNA 1-D-09, XIAP shRNA 1-E-01; B. Western blot analysis of KG-1 cells, from left to right, 
























Figure 4.44 Cell viability assay on XIAP knock down cells 
After XIAP knock down, HL-60 cells were more sensitive to TRAIL treatment. (24 hours 































5.1 There was a correlation of high survival with XIAP-low among M2 subtypes. 
Based on the dataset of human AML downloaded from GEO, the analysis of XIAP 
expression level among these samples grouped by FAB classification system and karyotypes 
indicates no significant difference. Besides, these AML patient samples were segregated into 
XIAP-high or XIAP-low based on median gene expression level, and Kaplan-Meier survival 
analysis indicated overall survival didn’t make a difference among XIAP-low and –high 
groups, either. 
However, analysis among each FAB groups showed there was a correlation of high survival 
with XIAP-low among M2 subtypes. On other subtypes, the correlation was not significant. 
This result suggested XIAP was probably an important marker for AML M2 subtype in clinic 
prognosis, and XIAP inhibitors would be hopefully practical on XIAP-high patients. 
5.2 RO-BIR2 monotherapy produced minimal effect on AML cell lines and moderate 
effect on AML patient samples 
The drug RO-BIR2 was designed to target XIAP BIR2 domain to reactivate caspase 3 and 
caspase 7 and induce cell apoptosis. However the monotherapy of RO-BIR2 resulted in little 
response on most AML cells (OCI-AML2, OCI-AML3, KG-1, HL-60 and MV4-11) even at a 
very high dose of 10 μM. U-937 cells and AML patient samples (AD450, AD330, AD448 
and SE211) had dose dependent response to RO-BIR2, but the IC50 was relatively high 
(above 10 μM). Besides, U-937 cells had the lowest XIAP expression level among all the 
AML cell lines and patient samples. 
RO-BIR2 monotherapy could induce a small amount of apoptotic cells accompanied with 
slight increase of activated caspase 3/7 on AML cells, but there was no significant change in 
the levels of apoptotic related proteins, such as XIAP, cleavage of caspase, etc. 
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5.3 RO-BIR2 combination therapy with TRAIL resulted in synergistic effect on AML 
cell lines and AML patient samples 
Combination of RO-BIR2 with TRAIL led to very high synergistic effect on both AML cell 
lines and AML patient samples with a low CI (CI<1). Combination therapy induced cells to 
undergo apoptosis process and led to specific apoptotic cell population increase, along with 
the activation of caspase 3/7. A number of apoptotic related proteins were changed upon 
combination therapy, such as XIAP, cleavage of caspase 3, cleavage of caspase 7, cleaved 
PARP, etc. 
The combination of RO-BIR2 with TRAIL possibly functioned by inhibiting XIAP and 
inducing caspase 3 and caspase 7 acitivities and downstream PARP cleavage, and processed 
to cell death finally. 
5.4 RO-BIR2 combination therapy with Ara-C resulted in synergistic effect on AML 
cell lines and AML patient samples 
Combination of RO-BIR2 with Ara-C had similar effect as TRAIL combination. RO-BIR2 
and Ara-C combination also led to synergistic effect on AML cell lines and AML patient 
samples with a low CI, but not as potent as RO-BIR2 and TRAIL combination. The 
combination could induce a number of cells undergoing apoptosis followed by the increase of 
apoptotic cell population, which was accompanied by the caspase 3/7 activity increase. 
Apoptotic related proteins were found changed as well, such as cleavage of caspase 3, 
cleavage of caspase 7, cleaved PARP, etc. 
However, RO-BIR2 and Ara-C combination didn’t work well on every AML cell lines we 
tested. KG-1 cells didn’t have a good response to this combination treatment, and the 
apoptosis assay and western blot analysis showed of the change apoptotic related protein 
levels is not significant. 
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Besides, though combination of RO-BIR2 with TRAIL or Ara-C both resulted in synergistic 
effect on AML cell lines and patient samples, Ara-C’s performance was not as potent as 
TRAIL. RO-BIR2 and TRAIL combination therapy could achieve high inhibition of cell 
viability and great increase of apoptotic cell population at a low concentration, thus reduce 
the toxicity and side effect, which was of great significance on AML patient treatment. In 
summarize, TRAIL was worthy of further investigation and development for possible clinical 
application. 
5. 5 Down-regulated genes of U-937 cells involved in immune response 
Microarray was used to detect the underlying mechanism of U-937’s different response to 
RO-BIR2 compared to other AML cell lines and patient samples, which showed there were a 
number of down-regulated genes on RO-BIR2 treated U-937 compared to OCI-AML3. 
Analysis of these genes by GEP and IPA indicated a significant number of genes involvement 
in immune response. 
5. 6 XIAP shRNA played a mimic role of XIAP inhibitors 
XIAP knock down by XIAP shRNA had better efficiency on HL-60 cells compared to KG-1 
cells. This is consistent with the data of RO-BIR2 monotherap. Knock down of XIAP led to 
XIAP decrease of expression level, inhibition of cell viability and some cleavage of caspase 
and cleavage of PARP. These results suggested the mimic function of XIAP shRNA as XIAP 
inhibitor, and support the idea that XIAP was an important target to promote apoptosis and 
lead to cell death. 
Besides, AML cells upon XIAP knock down become more sensitive to drugs compared to 
normal AML cells, which inspired us cells with XIAP inhibitor treatment probably had the 








6.1. Novelty of findings 
6.1.1 Combination of RO-BIR2 with TRAIL was more promising than Ara-C 
Though both combination of RO-BIR2 with TRAIL and Ara-C led to synergistic effect on 
AML cell lines and patient samples, the former had more promising result. At low doses of 
RO-BIR2 and TRAIL, the affection of combination therapy on AML cells and patient 
samples was already quite good, while combination of RO-BIR2 with Ara-C was less 
effective. For AML patients, it was of great significance to reduce drug dose but achieve the 
expected treatment outcome and lower side effects and drug toxicity. To achieve this goal, 
drug TRAIL had better prospects than Ara-C, though Ara-C was a standard cheo-drug and 
widely used to treat AML patient currently. 
This finding may related to TRAIL functioned by activating the extrinsic pathway and Ara-C 
activating the intrinsic pathway. Based on the analysis in this project, further investigation 
and development for possible clinical application of TRAIL was worthily. 
6.1.2 KG-1 cells were resistant to RO-BIR2 and Ara-C combination therapy 
Most of the AML cell lines and patient samples had good response to RO-BIR2 and Ara-C 
combination therapy, with the decrease of cell viability, increase of apoptotic cell population, 
activation of caspase 3/7 and changes of apoptotic proteins expression levels. However, KG-1 
cells behaved differently. 
KG-1 cells were regarded as resistant to this combination therapy. Though cell viability assay 
also showed some synergistic effect, the apoptosis assay and western blot results were not 
optimistic. Besides, it was more difficult to knock down XIAP on KG-1 cells compared to 
HL-60 cells. All these finding drew our attention, and the mechanism of KG-1 cells’ 
resistance was worthy of studying, and microarray was considerable to detect genes that 
involved in these process. 
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6.1.3  In order drug treatment probably could led to better outcomes 
XIAP knock down displayed XIAP shRNA had mimic function as XIAP inhibitors, which 
suggested the research of XIAP targeting drugs were quite promising. Moreover, AML cells 
upon XIAP knock down become more sensitive to TRAIL treatment, which inspired us the 
possibility of in order treatment of RO-BIR2 combination therapy (RO-BIR2 treatment first, 
and TRAIL or chemo-drugs 24 hours later). In clinic, drugs to treat APL also follows “7+3” 
discipline, which suggested drugs treated in order probably would lead to better outcomes. 
 
6.2 Limitations of the study 
There are some different ways to target the apoptotic mechanism, and some of them have 
been tested in cancer and stepped into clinical trial, such as Bcl-2 inhibitors and BH3 
mimetics (i.e. ABT-737) [92-94], BIR3 inhibitors [95], peptides (i.e. Smac-based 
peptide)[96], etc. To have a better understanding of the role of XIAP modulating cell death 
signalling pathways, it is necessary to refer to other inhibitors targeting apoptosis, and study 
the function networks related, which is also our plan for future study. 
Besides, animal experiment is of great importance for drug development. Due to the time 
limit, we hadn’t finished this part. Hopefully RO-BIR2 and combination therapy also worked 
well on mice, and this new drug could step into clinical trial phase. 
 
6.3 Future prospects 
6.3.1 Study the mechanism of KG-1 and U-937 cells’ responses to drugs 
KG-1 cell’s response drew our attention that it had worse response to RO-BIR2 and Ara-C 
combination therapy. The mechanism of AML cells’ resistance to RO-BIR2 was worthy of 
studying, and KG-1 cells would be a good model. 
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U-937 cells’ dose-dependent response was different from other AML cell lines, and GEP and 
IPA analysis had been down. The future plan is to study the upstream pathway and functional 
networks of the unique down-regulated genes involved. Furthermore, refer to other XIAP 
inhibitors and peptides and their working mechanism, the role of XIAP in apoptosis process 
could be better understood. 
6.3.2 Possible animal studies  
Mice work is planned for our future work. RO-BIR2 and combination treatment are designed 
on mice. 
6.3.3 XIAP shRNA and RO-BIR2 combination therapy 
As indicated by cell viability assay, apoptosis assay and western blot analysis, XIAP shRNA 
had mimic function as XIAP inhibitors. It is interesting to do some combination treatment of 
them to see whether there is some additional effect on AML cells and patient samples. 
6.3.4 Combination treatment in order on AML cells and patient samples 
XIAP shRNA experiments revealed that AML cells with XIAP knock down become more 
sensitive to TRAIL, and we hypothesized combination treatment in order probably led to 
better outcomes. Thus the new combination treatment is designed on AML cells and patient 
samples, to see if this method really works better and applicable on clinic. 
 
6.4 Clinical implications 
It is inspiring if RO-BIR2 could step into clinical phase and move further on drug discovery 
of BIR2 inhibitors. Besides, the result of RO-BIR2 and TRAIL combination stresses the 
importance of TRAIL on combination therapy, and it is possibly applicable on clinical trial. 
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Moreover, our studies showed the correlation of XIAP-high and poor overall survival on 
AML patients who belong to M2 subtypes. It is very interesting to do some further research 
on M2 subtypes to verify this correlation, perform more studies on AML M2 cells’ drug 
response and apoptosis pathway, and set a guidance of treatment on AML M2 patients. 
  
6.5 Proposed Model 
Based on the collective results of Chapter 4 and Chapter 5, we proposed a model of RO-BIR2 
combination therapy (Figure 6.1).  
RO-BIR2 binds to BIR2 domain, and the release of caspase 3 and caspase 7 affect the 
downstream cleavage of PARP, thus leading to the process of cell death. TRAIL could trigger 
the extrinsic pathway, and the activation of caspase 8 induces downstream executioner 
caspase, caspase 3 and caspase 7 and PARP cleavage, and finally processes to apoptosis. 
Chemo-drug Ara-C functioned more on intrinsic pathway by DNA damage and involved the 
function of mitochondria. The cleavage of caspase 9 also leads the downstream caspase 3/7 
and PARP cleavage and undergoes apoptosis. Besides, by knock down XIAP, XIAP shRNA 
had mimic function as RO-BIR2. (Figure 6.1) 
Finally, there are still many questions to be studied in detail, including how the down-
regulated genes on U-937 cells function and involve in immune response and affect the 
response to RO-BIR2, whether this new drug also works on animals, the mechanism of KG-1 
cells’ resistance to RO-BIR2 and Ara-C combination therapy, etc. These questioned are listed 
in our future prospects, and we aim to do further investigations and seek answers of them, 
and propose a more detailed model of RO-BIR2 combination therapy, and the associates with 
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Appendix 1. Unique up-regulated genes in RO-BIR2 treated U-937 cells  
Transcripts 
Cluster Id p  FC (abs) Regulation genesymbol 
7978568 0.00162 3.378631 up RNU1-1|RNU1-2|RNU1-3|RNU1-4|RNU1-5|RNU1-7|RNU1-8|GSTM2 




7951662 0.019213 2.82357 up CRYAB 
8112176 0.015456 2.680385 up RNU6ATAC 
7952335 0.027558 2.59526 up SNORD14E 
7908409 0.021586 2.569868 up RGS2 
8142524 0.020837 2.169704 up TSPAN12 
7912157 0.01555 2.148077 up ERRFI1 
7986350 0.03601 2.145216 up ARRDC4 
7920228 0.00217 2.142019 up PGLYRP4 
8058765 0.004375 2.107194 up FN1 
7948839 7.93E-04 2.103153 up NXF1 





Appendix 2. Unique down-regulated genes in RO-BIR2 treated U-937 cells  
Transcripts 
Cluster Id p  FC (abs) 
FC(abs) 
changed Regulation genesymbol 
8042391 4.27E-04 26.83548 -26.8355 down PLEK 
7902553 0.001391 18.42363 -18.4236 down IFI44 
7978351 0.004131 14.84928 -14.8493 down CTSG 
8046695 3.79E-04 14.46459 -14.4646 down ITGA4|CERKL 
7973110 7.16E-04 14.38979 -14.3898 down RNASE2 
7929065 5.13E-04 14.12243 -14.1224 down IFIT1 
7988644 5.43E-04 14.01243 -14.0124 down ATP8B4 
8101126 0.008188 13.12488 -13.1249 down CXCL10 
8056257 3.39E-04 12.81022 -12.8102 down FAP 
8140967 2.97E-04 12.26619 -12.2662 down SAMD9 
8068697 0.001367 11.65151 -11.6515 down MX2 
8113504 4.13E-04 11.62298 -11.623 down C5orf13 
8006531 0.002616 11.58506 -11.5851 down SLFN5 
7902541 0.001499 11.43956 -11.4396 down IFI44L 
8139033 1.51E-04 11.06215 -11.0621 down AOAH 
7973108 0.012562 10.8698 -10.8698 down ECRP 
7973105 0.001183 10.84043 -10.8404 down RNASE3 
8173745 0.001109 10.34157 -10.3416 down CYSLTR1 
7938035 2.80E-05 10.10767 -10.1077 down TRIM22 
8140971 4.57E-04 10.06662 -10.0666 down SAMD9L 
7906377 4.70E-04 9.794483 -9.79448 down MNDA 
7961069 7.64E-04 9.122169 -9.12217 down CLECL1 
7906400 1.06E-04 9.075195 -9.0752 down IFI16 
7929052 0.001468 8.755398 -8.7554 down IFIT3 
8056285 0.011981 8.723834 -8.72383 down IFIH1 
8083422 0.002392 8.485424 -8.48542 down SUCNR1 
8060940 0.00372 8.295997 -8.296 down C20orf103 
8096361 0.001936 8.152587 -8.15259 down HERC5 
8179731 9.66E-04 8.1442 -8.1442 down HLA-B 
7958884 2.29E-04 8.063546 -8.06355 down OAS1 
8055465 9.14E-04 8.015986 -8.01599 down CXCR4 
7925257 5.90E-04 7.936393 -7.93639 down LYST 
7953901 2.80E-04 7.920091 -7.92009 down CLEC12A 
7958913 8.83E-05 7.907724 -7.90772 down OAS2 
8059413 0.001553 7.887262 -7.88726 down DOCK10 
8179041 0.008507 7.795073 -7.79507 down HLA-A 
8131844 1.11E-04 7.647681 -7.64768 down GPNMB 
8017599 0.00285 7.614577 -7.61458 down PECAM1 
8178498 0.001976 7.50375 -7.50375 down HLA-B|HLA-C 
7983512 0.013195 7.457278 -7.45728 down SQRDL 
8124911 0.002784 7.427122 -7.42712 down HLA-B|HLA-C 
8168691 2.34E-04 7.416279 -7.41628 down DIAPH2 
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7906777 0.002315 7.403164 -7.40316 down FCGR2B 
8179049 0.019707 7.249031 -7.24903 down HLA-J|HLA-A 
8111739 3.48E-04 7.214463 -7.21446 down FYB 
8125500 0.009538 7.128823 -7.12882 down PSMB8 
8178855 0.010048 7.093197 -7.0932 down PSMB8 
8180049 0.010446 7.061737 -7.06174 down PSMB8 
7990555 0.006408 7.060512 -7.06051 down NRG4 
8103601 0.002867 6.928909 -6.92891 down DDX60L 
8157038 0.008432 6.894729 -6.89473 down SLC44A1 
8171896 0.006898 6.885185 -6.88519 down CXorf21 
7995697 9.03E-04 6.842628 -6.84263 down LPCAT2 
7914127 5.32E-04 6.721611 -6.72161 down IFI6 
8001457 0.002476 6.710938 -6.71094 down CES1 
8171684 5.20E-04 6.619889 -6.61989 down SH3KBP1 
8177732 0.001577 6.598981 -6.59898 down HLA-A|HLA-B 
7961532 0.006862 6.574055 -6.57406 down ARHGDIB 
8028104 0.001095 6.445859 -6.44586 down HCST 
8042356 0.001924 6.28432 -6.28432 down MEIS1 
8103563 1.29E-04 6.280336 -6.28034 down DDX60 
8117800 0.001105 6.11823 -6.11823 down HLA-A|HLA-B 
8179331 0.005725 6.10948 -6.10948 down C2|CFB 
8056201 0.005233 6.076554 -6.07655 down RBMS1 
8061416 1.20E-05 6.067491 -6.06749 down CST7 
7929047 0.001172 5.966056 -5.96606 down IFIT2 
8178095 0.005524 5.953918 -5.95392 down C2|CFB 
8070826 7.80E-04 5.942668 -5.94267 down ITGB2 
8074237 7.37E-04 5.886754 -5.88675 down CECR1 
8143471 6.89E-04 5.846325 -5.84633 down CLEC5A 
8153002 0.002102 5.840493 -5.84049 down NDRG1 
8006433 0.003575 5.814852 -5.81485 down CCL2 
8117813 1.76E-04 5.809734 -5.80973 down HLA-J|HLA-A 
7908553 7.98E-04 5.801886 -5.80189 down PTPRC 
7948332 0.001115 5.784546 -5.78455 down LPXN 
8172766 0.00135 5.756281 -5.75628 down XAGE1A|XAGE1B| XAGE1C|XAGE1D|XAGE1E 
8178489 7.40E-06 5.718628 -5.71863 down HLA-C 
8167701 0.001394 5.717902 -5.7179 down XAGE1A|XAGE1B| XAGE1C|XAGE1D|XAGE1E 
8065359 9.48E-04 5.6963 -5.6963 down CD93 
8160346 3.42E-04 5.662373 -5.66237 down PTPLAD2|KIAA1 797 
8064790 0.001187 5.630771 -5.63077 down RASSF2 
7969986 0.00562 5.597798 -5.5978 down TNFSF13B 
8124901 1.02E-04 5.593792 -5.59379 down HLA-C|HLA-B 
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7991335 2.21E-04 5.58803 -5.58803 down ANPEP 
8040163 0.001266 5.539097 -5.5391 down IAH1|ADAM17 
7972557 0.007426 5.468081 -5.46808 down GPR183 
7940237 0.0022 5.457385 -5.45738 down MS4A4A 
7956878 0.001604 5.457136 -5.45714 down IRAK3 
7961091 0.009723 5.394054 -5.39405 down CLEC2A 
8177725 2.82E-04 5.382844 -5.38284 down HLA-G 
8046380 0.001414 5.335917 -5.33592 down ITGA6 
8179034 1.47E-04 5.314727 -5.31473 down HLA-G 
8170364 9.39E-04 5.282439 -5.28244 down AFF2 
8118324 4.40E-04 5.280962 -5.28096 down C2|CFB 
8179276 0.00104 5.244036 -5.24404 down AIF1 
8177996 9.72E-04 5.235283 -5.23528 down AIF1 
8118158 0.001114 5.227753 -5.22775 down AIF1 
8046003 0.001127 5.22306 -5.22306 down GCA 
8089911 0.003774 5.207693 -5.20769 down HCLS1 
8174201 0.010567 5.200893 -5.20089 down BEX1 
7908376 0.004694 5.18636 -5.18636 down RGS18 
7939120 0.017398 5.160326 -5.16033 down RCN1 
8138805 0.002685 5.078258 -5.07826 down CPVL 
8014066 8.64E-04 5.018304 -5.0183 down EVI2A 
8069644 4.04E-05 5.007587 -5.00759 down APP 
8116734 0.001798 5.004383 -5.00438 down LY86 
7957023 6.51E-04 4.919727 -4.91973 down LYZ 
8160559 7.49E-04 4.910001 -4.91 down DDX58 
8085716 0.004116 4.871434 -4.87143 down SATB1 
7997712 0.007966 4.841015 -4.84102 down IRF8 
7898655 0.001786 4.833491 -4.83349 down CDA 
8156321 0.001684 4.776527 -4.77653 down SYK 
7945132 2.59E-04 4.763033 -4.76303 down FLI1|EWSR1 
7971461 7.12E-04 4.727784 -4.72778 down LCP1 
8049246 0.001856 4.710836 -4.71084 down INPP5D 
7955908 0.00203 4.698818 -4.69882 down NCKAP1L 
8166730 0.001248 4.669551 -4.66955 down CYBB 
7953428 0.007321 4.663072 -4.66307 down CD4 
7919800 0.00843 4.65433 -4.65433 down CTSS 
8152606 0.021593 4.653938 -4.65394 down SNTB1 
8126428 5.81E-04 4.644927 -4.64493 down TRERF1 
8024056 7.70E-04 4.642034 -4.64203 down ELANE 
8173444 0.003111 4.569564 -4.56956 down IL2RG 
8154100 8.66E-04 4.549172 -4.54917 down VLDLR 
8109843 2.43E-04 4.501125 -4.50113 down DOCK2|DOCK5 
7982256 0.001506 4.487415 -4.48742 down GOLGA8IP|LOC728 047|LOC643699 
8088803 0.002998 4.48341 -4.48341 down EIF4E3 
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7935337 9.21E-04 4.482842 -4.48284 down PIK3AP1 
7945666 0.001263 4.480972 -4.48097 down CTSD 
8051573 0.002647 4.463947 -4.46395 down CDC42EP3 
8022118 0.001443 4.462404 -4.4624 down EPB41L3 
7921434 0.004051 4.451848 -4.45185 down AIM2 
8112007 0.006395 4.444244 -4.44424 down EMB 
7990818 0.003349 4.440219 -4.44022 down BCL2A1 
8090018 6.65E-05 4.43945 -4.43945 down PARP9 
7954631 2.87E-04 4.436552 -4.43655 down FAR2 
7994826 0.003515 4.409941 -4.40994 down ITGAL 
7944667 3.65E-04 4.388956 -4.38896 down SORL1 
8117777 0.003524 4.268862 -4.26886 down HLA-H|HLA-G| HLA-A|HLA-B 
8103951 0.008474 4.267958 -4.26796 down ACSL1 
7973101 0.003658 4.150681 -4.15068 down RNASE6 
8152988 0.010114 4.135242 -4.13524 down SLA 
7969129 0.003073 4.133538 -4.13354 down PHF11 
7923547 0.001119 4.129515 -4.12952 down CHI3L1 
8145470 3.92E-04 4.112575 -4.11257 down DPYSL2 
8113130 0.00831 4.107356 -4.10736 down MCTP1 
7951686 0.006511 4.081534 -4.08153 down IL18 
7935058 1.12E-04 4.072053 -4.07205 down MYOF 
8001531 0.019723 4.062272 -4.06227 down MT1G 
8038809 3.33E-04 4.05926 -4.05926 down NKG7 
7901951 0.002813 4.039341 -4.03934 down PGM1 
8055980 0.003421 4.034658 -4.03466 down CYTIP 
7953914 0.010784 4.032901 -4.0329 down CLEC12B 
8082058 0.001715 4.025164 -4.02516 down CSTA 
7953569 0.001796 4.012745 -4.01275 down PTPN6 
8014316 0.001164 4.011839 -4.01184 down CCL5 
7976402 0.00731 3.995782 -3.99578 down COX8C 
8020630 0.00191 3.988281 -3.98828 down TTC39C 
8008646 5.90E-04 3.952115 -3.95212 down SCPEP1 
8108873 7.56E-04 3.943923 -3.94392 down ARHGAP26 
7922773 0.002282 3.941893 -3.94189 down NCF2 
7908161 4.73E-04 3.910803 -3.9108 down C1orf21 
8179103 3.29E-04 3.901978 -3.90198 down HLA-E|HLA-B 
8177788 2.61E-04 3.882304 -3.8823 down HLA-E|HLA-B 
8134814 0.00635 3.881429 -3.88143 down PILRA 
7961083 0.007958 3.869652 -3.86965 down CLEC2B 
7958895 0.003317 3.861008 -3.86101 down OAS3 
7909371 0.006084 3.84315 -3.84315 down CR1 
7940153 0.003191 3.833536 -3.83354 down FAM111A 
8122464 0.00562 3.832552 -3.83255 down UTRN 
8072744 1.22E-04 3.827334 -3.82733 down NCF4 
8113358 0.001407 3.782508 -3.78251 down ST8SIA4 
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7917912 0.008747 3.769483 -3.76948 down DPYD 
8025103 0.008066 3.769435 -3.76943 down EMR1 
8033257 0.001964 3.757591 -3.75759 down C3 
8117890 3.54E-05 3.755622 -3.75562 down HLA-E|HLA-B 
7918857 0.002489 3.752133 -3.75213 down TSPAN2 
8139057 0.003251 3.704075 -3.70408 down ELMO1 
7925531 0.005672 3.691339 -3.69134 down AKT3 
7985695 0.008968 3.682271 -3.68227 down AKAP13 
8171105 0.026193 3.67115 -3.67115 down CRLF2 
8152976 0.010186 3.67028 -3.67028 down TMEM71 
8071036 0.011997 3.663357 -3.66336 down S100B 
7906720 7.12E-04 3.662465 -3.66247 down FCER1G 
7904303 3.67E-04 3.658979 -3.65898 down CD101 
7918157 1.92E-04 3.65512 -3.65512 down VAV3 
8014063 1.74E-04 3.654801 -3.6548 down EVI2B 
8175393 5.29E-04 3.589364 -3.58936 down ARHGEF6 
7918657 0.00116 3.546452 -3.54645 down PTPN22 
8036710 0.002658 3.534865 -3.53487 down GMFG 
8142452 0.001054 3.531468 -3.53147 down TFEC 
7920258 0.004965 3.519034 -3.51903 down S100A6 
7937330 0.00177 3.518456 -3.51846 down IFITM2 
7951372 0.009685 3.497079 -3.49708 down CASP4 
8174207 0.002489 3.456442 -3.45644 down NXF3 
7963289 0.004728 3.4474 -3.4474 down BIN2 
8140227 0.00536 3.401447 -3.40145 down NCF1|NCF1C| NCF1B 
8121277 0.022618 3.397218 -3.39722 down AIM1 
8091537 0.002059 3.377183 -3.37718 down IGSF10|MED12L 
8082075 0.005424 3.373536 -3.37354 down DTX3L|PARP9 
8145365 0.002182 3.371426 -3.37143 down DOCK5 
8139433 0.001695 3.370669 -3.37067 down MYO1G 
8137250 0.001987 3.341385 -3.34138 down GIMAP2 
8086600 0.008325 3.317094 -3.31709 down CCR1 
8013450 0.00336 3.308362 -3.30836 down LGALS9B| LGALS9C 
8096335 8.36E-04 3.298641 -3.29864 down HERC6 
7934920 0.014108 3.298084 -3.29808 down LIPA|LOC100509637 
8131614 0.007804 3.296696 -3.2967 down AHR 
8133314 0.00826 3.293544 -3.29354 down NCF1|NCF1C|NCF1B 
8081219 1.74E-05 3.277456 -3.27746 down ST3GAL6 
7960874 0.001449 3.262682 -3.26268 down C3AR1 
8157524 0.001613 3.257622 -3.25762 down TLR4 
7972548 0.002364 3.241773 -3.24177 down GPR18 
8133518 0.006827 3.229276 -3.22928 down NCF1|NCF1C|NCF1B 
7916986 0.001626 3.227816 -3.22782 down NEGR1 
8036224 9.39E-04 3.225673 -3.22567 down TYROBP|ZNF160 
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8021635 0.026766 3.215715 -3.21572 down SERPINB2 
7971573 0.002753 3.185926 -3.18593 down RCBTB2 
7968637 0.008323 3.172028 -3.17203 down CCNA1 
8056860 6.19E-04 3.163125 -3.16313 down WIPF1 
8178211 0.00132 3.1555 -3.1555 down PSMB9 
7968344 0.00437 3.152595 -3.1526 down ALOX5AP 
8039257 0.00506 3.139716 -3.13972 down LAIR1 
7995681 4.29E-04 3.138536 -3.13854 down MMP2 
7921752 0.001551 3.135878 -3.13588 down ARHGAP30 
8118571 0.001747 3.135516 -3.13552 down PSMB9 
8179495 0.001918 3.124438 -3.12444 down PSMB9 
7964119 0.003021 3.11819 -3.11819 down STAT2 
8166184 0.025648 3.114433 -3.11443 down CA5B 
8021301 0.007581 3.113144 -3.11314 down RAB27B 
8082003 0.011331 3.108425 -3.10843 down EAF2 
8157650 0.006096 3.100099 -3.1001 down PTGS1 
7943240 0.001419 3.085456 -3.08546 down PIWIL4 
8151952 0.004615 3.084388 -3.08439 down NIPAL2 
8084794 0.004818 3.065601 -3.0656 down IL1RAP 
8080781 0.006221 3.064543 -3.06454 down PXK 
8115147 5.54E-04 3.057275 -3.05728 down CD74 
8178811 0.00558 3.054065 -3.05406 down HLA-DRB4|HLA- DRB1 
8162059 0.001029 3.044833 -3.04483 down SLC28A3 
8057744 0.003784 3.042984 -3.04298 down STAT1 
7921677 0.011799 3.028582 -3.02858 down CD244 
8133876 4.46E-04 3.02683 -3.02683 down CD36 
8030277 0.001012 3.026024 -3.02602 down CD37 
7903980 0.001142 3.01911 -3.01911 down C1orf162 
7968417 6.27E-04 3.012983 -3.01298 down FRY 
7951397 0.001403 3.006734 -3.00673 down CASP1 
8078350 6.29E-04 2.996084 -2.99608 down TGFBR2 
7912224 8.14E-04 2.962248 -2.96225 down SLC2A5 
7930498 0.009648 2.960707 -2.96071 down ACSL5 
8013272 0.011123 2.936728 -2.93673 down CCDC144B|CCDC144A| CCDC144C 
8166511 1.02E-05 2.933622 -2.93362 down PDK3 
7926786 0.005997 2.930478 -2.93048 down APBB1IP 
8018966 0.018014 2.92696 -2.92696 down TIMP2 
8180003 0.005512 2.922062 -2.92206 down HLA-DRB3 
7917532 0.002908 2.916814 -2.91681 down GBP2 
7923406 0.00382 2.916759 -2.91676 down PTPN7 
8005458 0.021337 2.912864 -2.91286 down LGALS9C|LGALS9B 
8166278 0.001727 2.910518 -2.91052 down SCML1 
7932160 0.006835 2.895009 -2.89501 down FAM107B 
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8119102 0.001645 2.894453 -2.89445 down RAB44 
8076704 0.009844 2.87716 -2.87716 down SMC1B 
8002778 0.002356 2.87687 -2.87687 down MLKL 
7909455 0.002361 2.87391 -2.87391 down TRAF3IP3 
8042310 0.001509 2.864196 -2.8642 down SLC1A4 
7920244 0.009916 2.828223 -2.82822 down S100A8 
7992181 0.002206 2.808087 -2.80809 down TPSAB1|TPSB2 
7998434 0.002803 2.801813 -2.80181 down TPSAB1|TPSB2 
8061668 0.015557 2.796155 -2.79615 down HCK 
8025285 0.016687 2.793904 -2.7939 down C19orf59 
7939341 0.001651 2.783929 -2.78393 down CD44 
8118149 0.008538 2.779475 -2.77948 down LST1 
8177988 0.008744 2.771128 -2.77113 down LST1 
8179268 0.008702 2.761778 -2.76178 down LST1 
8089261 0.010812 2.756775 -2.75678 down CBLB 
7928534 0.003982 2.746025 -2.74602 down C10orf11 
7910387 0.012529 2.744534 -2.74453 down RHOU 
8024572 0.00585 2.736434 -2.73643 down GNA15 
8092392 0.002349 2.734106 -2.73411 down KLHL6 
8010983 0.003589 2.723702 -2.7237 down ABR 
8148476 6.69E-04 2.713802 -2.7138 down DENND3 
8030796 0.001345 2.708773 -2.70877 down SIGLECP3 
8045688 3.11E-05 2.702495 -2.70249 down TNFAIP6 
8130408 0.003165 2.693513 -2.69351 down IPCEF1 
8087485 0.006743 2.687504 -2.6875 down UBA7 
8122396 0.016796 2.682561 -2.68256 down AIG1 
8037374 0.006495 2.67822 -2.67822 down PLAUR 
7952601 0.004055 2.673421 -2.67342 down ETS1 
8167334 0.00222 2.670986 -2.67099 down WAS 
7990054 0.009009 2.670236 -2.67024 down UACA 
8014414 0.001198 2.663166 -2.66317 down CCL3L1|CCL3L3 
7989387 0.004996 2.65725 -2.65725 down VPS13C 
8014391 0.001127 2.657128 -2.65713 down CCL3L1|CCL3L3 
8019731 9.01E-04 2.653441 -2.65344 down CCL3L1|CCL3L3 
7940259 0.005384 2.653201 -2.6532 down MS4A7|MS4A14 
7984112 7.58E-04 2.648412 -2.64841 down RAB8B 
8042576 0.001685 2.639422 -2.63942 down NAGK 
8177717 0.010746 2.638747 -2.63875 down HLA-F 
8038861 0.002067 2.634186 -2.63419 down SIGLEC6 
8138749 5.77E-04 2.62734 -2.62734 down HOXA9|HOXA10 
7897236 0.008766 2.621588 -2.62159 down KCNAB2 
7994769 0.012653 2.615205 -2.6152 down CORO1A 
8060758 0.011091 2.579795 -2.57979 down PRNP 
7997289 0.008743 2.5731 -2.5731 down CNTNAP4 
7988789 0.003705 2.564731 -2.56473 down DMXL2 
8096301 0.015274 2.561895 -2.56189 down SPP1 
135 
 
8047784 0.006435 2.556299 -2.5563 down ZDBF2 
8045539 0.004598 2.555508 -2.55551 down KYNU 
8152522 0.006357 2.547434 -2.54743 down ENPP2 
8003903 0.005598 2.543753 -2.54375 down ARRB2 
7964834 0.002357 2.542335 -2.54234 down CPM 
8165866 0.00701 2.538352 -2.53835 down STS 
8155930 0.006149 2.531496 -2.5315 down GCNT1 
8014233 0.003011 2.530332 -2.53033 down SLFN11 
8054308 6.30E-05 2.528939 -2.52894 down TBC1D8 
8056545 2.39E-04 2.527061 -2.52706 down STK39 
7961102 0.008292 2.518782 -2.51878 down CLEC1B 
8166469 0.004343 2.512541 -2.51254 down SAT1 
8139100 0.005776 2.510641 -2.51064 down TARP|TRGC2 
7911178 0.002128 2.50908 -2.50908 down NLRP3 
8050427 0.020045 2.508861 -2.50886 down FAM49A 
7927146 8.34E-04 2.491483 -2.49148 down CSGALNACT2 
8092169 0.002878 2.491294 -2.49129 down TNFSF10 
8081431 0.001825 2.476835 -2.47684 down ALCAM 
8059650 0.007726 2.468879 -2.46888 down SP110 
8102950 0.00358 2.468791 -2.46879 down INPP4B 
8103226 0.007059 2.464539 -2.46454 down TMEM154 
7988050 0.026104 2.464268 -2.46427 down TGM5 
7931226 0.008875 2.464105 -2.4641 down ZRANB1 
8082100 0.004904 2.463352 -2.46335 down PARP14 
7948420 0.004434 2.46108 -2.46108 down FABP5|FABP5P3 
8115234 0.002721 2.454703 -2.4547 down ANXA6 
8014369 4.53E-05 2.450315 -2.45032 down CCL3 
8147049 0.003564 2.448902 -2.4489 down FABP5|FABP5P3 
8138689 0.005514 2.437553 -2.43755 down SKAP2 
7987475 0.007094 2.435983 -2.43598 down PLCB2 
7964757 0.001131 2.431845 -2.43185 down RBMS1 
8047401 0.001574 2.425723 -2.42572 down 
8093950 0.030713 2.422701 -2.4227 down S100P 
8135363 0.002967 2.420111 -2.42011 down PIK3CG 
8117435 0.004453 2.41812 -2.41812 down BTN3A2 
8118945 0.008749 2.412294 -2.41229 down PPARD 
8005204 0.019831 2.412202 -2.4122 down CCDC144A|CCDC144B| CCDC144C 
8167971 0.010579 2.400405 -2.4004 down MIR223 
7981142 0.001232 2.396058 -2.39606 down CLMN 
8038877 0.027172 2.394104 -2.3941 down SIGLEC5 
8000200 0.034461 2.38045 -2.38045 down RRN3P1|RRN3P2 
8014241 0.008883 2.374074 -2.37407 down SLFN12 
8029551 0.031353 2.369427 -2.36943 down APOC2 
8079950 0.018553 2.366183 -2.36618 down GNAI2 
8151512 0.005153 2.358961 -2.35896 down PAG1 
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8152031 6.25E-04 2.356036 -2.35604 down FBXO43 
8113214 0.008706 2.35504 -2.35504 down GLRX 
7980146 0.005909 2.352581 -2.35258 down NPC2 
8117458 0.004866 2.350318 -2.35032 down BTN3A1 
8074606 0.038035 2.350099 -2.3501 down USP18|USP41 
8021653 0.004986 2.349947 -2.34995 down SERPINB8 
7988921 0.010143 2.341222 -2.34122 down MYO5A 
8081288 0.010704 2.339259 -2.33926 down TMEM45A 
8120602 0.008016 2.335038 -2.33504 down OGFRL1 
7917516 0.001852 2.334032 -2.33403 down GBP1|GBP3 
7974341 0.007602 2.333867 -2.33387 down GNG2 
8149927 0.017719 2.330871 -2.33087 down CLU 
8155192 0.001428 2.330189 -2.33019 down GLIPR2 
8179019 0.013666 2.328966 -2.32897 down HLA-F 
7933105 0.013773 2.325525 -2.32553 down ZNF25 
8004510 0.008499 2.325504 -2.3255 down CD68 
7932867 0.00261 2.32183 -2.32183 down ZNF438 
7968872 0.009931 2.304873 -2.30487 down DNAJC15 
7945962 0.003985 2.303211 -2.30321 down TRIM21 
8095680 0.004496 2.297093 -2.29709 down IL8 
8119525 0.0462 2.296751 -2.29675 down HCRP1 
7927964 2.18E-04 2.293632 -2.29363 down SRGN 
8038029 0.008717 2.292248 -2.29225 down CARD8 
8166243 0.006937 2.292093 -2.29209 down REPS2 
8072710 0.003511 2.289182 -2.28918 down APOL6 
8020668 0.026303 2.287008 -2.28701 down IMPACT 
8146660 0.014766 2.281011 -2.28101 down DNAJC5B 
7917576 0.007754 2.280207 -2.28021 down GBP5 
7969114 0.004011 2.278183 -2.27818 down SETDB2 
8126402 0.003101 2.276345 -2.27634 down TRERF1 
8165735 1.23E-04 2.271871 -2.27187 down CSF2RA 
7964701 0.003121 2.27059 -2.27059 down GNS 
8169541 0.001719 2.266363 -2.26636 down DOCK11 
7928671 0.010926 2.262286 -2.26229 down C10orf57 
8123598 0.007219 2.255635 -2.25563 down SERPINB1 
8080487 7.94E-04 2.248852 -2.24885 down PRKCD 
8119096 0.014177 2.245213 -2.24521 down RAB44 
8176306 1.07E-04 2.245147 -2.24515 down CSF2RA 
7970602 7.69E-04 2.243913 -2.24391 down PARP4 
8062444 0.002695 2.235658 -2.23566 down BPI 
7906767 0.015488 2.23549 -2.23549 down FCGR2C|FCGR2B 
7995797 0.010923 2.23148 -2.23148 down MT1E 
7995096 0.007902 2.23119 -2.23119 down ITGAM 
8085628 0.00995 2.230716 -2.23072 down ANKRD28 
8104131 0.028838 2.227857 -2.22786 down MGC39584 
8166906 2.48E-04 2.226925 -2.22693 down GPR34 
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7991581 0.027346 2.226195 -2.2262 down CHSY1 
8035896 2.47E-04 2.221388 -2.22139 down TSHZ3 
8136557 5.41E-04 2.221256 -2.22126 down TBXAS1 
7938012 0.001428 2.220631 -2.22063 down TRIM6-TRIM34| TRIM78P 
8046408 7.25E-04 2.220324 -2.22032 down PDK1 
8025076 0.006601 2.214533 -2.21453 down VAV1 
7989516 0.006114 2.2133 -2.2133 down HERC1 
8123951 0.032202 2.210066 -2.21007 down C6orf105 
8173437 0.004388 2.207082 -2.20708 down CXorf65 
8067007 0.00127 2.204472 -2.20447 down TMSB4X|TMSL3| BCAS4|TMSL6 
7987027 7.18E-04 2.195814 -2.19581 down GOLGA8H|LOC643699| LOC728047|LOC653720 
8160332 0.00911 2.19255 -2.19255 down MLLT3 
8085581 8.57E-04 2.191785 -2.19179 down COLQ 
8009353 0.007175 2.187511 -2.18751 down PITPNC1 
8102482 0.005091 2.185175 -2.18517 down SEC24D 
8156060 0.001254 2.18007 -2.18007 down TLE4 
8171587 0.007022 2.168658 -2.16866 down PHKA2 
8077899 0.012623 2.167512 -2.16751 down PPARG 
7957260 0.004357 2.166794 -2.16679 down GLIPR1|KRR1 
7981068 0.024165 2.166196 -2.1662 down SERPINA1 
8083901 0.00365 2.165605 -2.1656 down FNDC3B 
8124307 0.013785 2.164164 -2.16416 down CMAH 
8158240 6.90E-04 2.155098 -2.1551 down TMSB4X|TMSL3| TMSL6 
7923378 0.01409 2.153855 -2.15386 down CSRP1 
8159850 0.024373 2.150493 -2.15049 down VLDLR|FLJ35024 
8084742 0.024969 2.138235 -2.13823 down LPP 
8060418 0.011764 2.136212 -2.13621 down SIRPA 
7946061 0.012488 2.133538 -2.13354 down HBE1 
8149986 0.021849 2.127453 -2.12745 down ZNF395|FBXO16 
7968703 0.004919 2.126765 -2.12677 down NHLRC3 
8000590 0.006669 2.123096 -2.1231 down SULT1A1 
8033605 0.049058 2.120468 -2.12047 down MYO1F 
7908694 0.021998 2.114216 -2.11422 down NAV1 
8168517 0.024648 2.105193 -2.10519 down LPAR4 
8166632 6.28E-04 2.098045 -2.09804 down GK 
8045499 0.003022 2.096734 -2.09673 down HNMT 
8012605 8.70E-05 2.09387 -2.09387 down GAS7 
8056113 0.002575 2.087932 -2.08793 down LY75 
7986214 0.018925 2.082026 -2.08203 down SLCO3A1 
8131957 0.027833 2.07938 -2.07938 down SNX10 
8091327 6.65E-04 2.077999 -2.078 down PLSCR1 
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7936064 8.27E-04 2.076263 -2.07626 down NT5C2 
7969166 0.007425 2.07241 -2.07241 down KCNRG|TRIM13 
8086125 0.021172 2.07216 -2.07216 down TRANK1 
8139121 0.008902 2.071439 -2.07144 down TRGV3|TARP 
7990211 0.005858 2.070696 -2.0707 down HEXA 
8170992 0.0055 2.068244 -2.06824 down SNORA56 
8044391 0.004281 2.063473 -2.06347 down MERTK 
8059680 0.048742 2.063473 -2.06347 down HTR2B 
8031207 0.015598 2.062394 -2.06239 down LILRA2 
8042416 0.004538 2.060497 -2.0605 down ARHGAP25 
7944722 0.017104 2.056894 -2.05689 down UBASH3B 
7985555 0.009318 2.054879 -2.05488 down EFTUD1|LOC648809 
7937940 0.01582 2.052026 -2.05203 down OR52K3P 
8062119 0.033902 2.050012 -2.05001 down MT1P3 
7935951 0.029283 2.049757 -2.04976 down C10orf76 
8160531 0.013142 2.046428 -2.04643 down C9orf72 
7923534 0.014774 2.044313 -2.04431 down MYBPH 
7991640 0.009381 2.040188 -2.04019 down TARSL2 
7990417 4.32E-04 2.040151 -2.04015 down SCAMP2 
7971653 0.009902 2.040072 -2.04007 down DLEU2 
7975416 0.002068 2.039203 -2.0392 down PCNX 
8125512 0.009618 2.036865 -2.03687 down TAP1 
7940869 0.014125 2.033826 -2.03383 down FERMT3 
8178867 0.009174 2.03348 -2.03348 down TAP1 
8041422 0.006503 2.03197 -2.03197 down RASGRP3 
8180061 0.008833 2.031159 -2.03116 down TAP1 
7971388 0.005979 2.028861 -2.02886 down SLC25A30 
7958253 0.003237 2.023119 -2.02312 down C12orf75 
7940216 0.006923 2.020897 -2.0209 down MS4A3 
8174103 0.001104 2.017544 -2.01754 down GK|GK3P 
8099073 0.04307 2.017072 -2.01707 down LRPAP1 
7990092 0.0086 2.016635 -2.01664 down MYO9A 
7965964 0.015028 2.016189 -2.01619 down SLC41A2 
8031293 0.033942 2.016177 -2.01618 down KIR2DL3|KIR2DL1| KIR2DL2 
8167006 0.002992 2.014983 -2.01498 down RP2 
8170998 0.017684 2.011739 -2.01174 down F8A1|F8A2|F8A3 
8121087 0.013448 2.008214 -2.00821 down PM20D2 





Appendix 3. Primer sequences used for qRT-PCR analysis 
 
Primer 
Forward primer Reverse primer Gene ID 
XIAP P1 TGGGGTTCAGTTTCAAGGAC TGCAACCAGAACCTCAAGTG






PLEK TTGAGAGGCTGTGTGGTGAC  TGGCTCTGATCCACTCTGTG
SAMD9L CTGGCCAGAAAATCAAGAGC  AAAAGTGTGCTTGCCTGCTT
TRIM22 CTGTGCCTCCCTGTCGTATT  CTCCGTGGTTTGTGACATTG
MNDA TTGCCAAAGATATGCCATCA  GGAATCCTCCCTCTTGCTTC
OAS2 TTAAGAGGCAACTCCGATGG  TGAACCCATCAAGGGACTTC
CLEC2A GGCCTTATGTGCTTCCTGAG  CTCTCACTCCAAGCCAGTCC
AFF2 AGAGACTGGGACTTGGAGCA  TTGTATGGCTCCCCAAAAAG
MYO9A AGCTCTTGCCCAAAAAGACA  TTGGCATGGACTTCCTTTTC
RCBTB2 TTTGCAGAAATGGACCATGA  CAACTCTGCTTGCTTTGCTG
SCML1 TCAACTGACCATGCTTCTGC  CCGTCAATTTCATGGCTTCT
HEXA CTTCGGTGAGGACTTCAAGC  ATATCCTCTCGCCACACCTG
CECR1 TTCTGGATGCTCTGATGCTG  GCTACAGGGTGGTTCCTCAA
AIF1 CAGGAAGAGAGGCTGGATGA AGCAGGAAGAGAGGCTGGAT
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